| Excerpt | Reference |
|---|
| "Hepatic cirrhosis is frequently associated with glucose intolerance and insulin resistance, but the mechanisms underlying the insulin insensitivity are unknown." | ( Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AJ; Record, CO, 1992) |
| "Variable degrees of liver fibrosis are noted in other inborn defects of the urea cycle, eg, in ornithine transcarbamylase and carbamoylphosphate synthetase deficiencies." | ( Bachmann, C; Baumgartner, R; Zimmermann, A, 1986) |
| "Hepatic cirrhosis is infrequently diagnosed in young adults." | ( Enlow, RW; Fotino, M; Gelb, AM; Kreek, MJ; Novick, DM; Schoenberg, MD; Stenger, RJ; Winter, JW; Yancovitz, SR, 1985) |
| "We conclude that liver cirrhosis is characterized by an abnormal branched-chain amino acid response to protein ingestion, which matches the well-known intolerance to oral glucose." | ( Bianchi, G; Bua, V; Dondi, C; Forlani, G; Marchesini, G; Melli, A; Pisi, E; Vannini, P; Zoli, M, 1983) |
| "Zinc deficiency in liver cirrhosis is probably caused by portosystemic shunting, whereas in Crohn's disease abnormalities of protein metabolism are suggested as etiologic factor." | ( Büchsel, R; Gerok, W; Köttgen, E; Löhle, E; Schölmerich, J; Wietholtz, H, 1984) |
| "Liver fibrosis is accompanied by significant increase of collagen content in this organ." | ( Bańkowski, E, 1994) |
| "Advanced liver fibrosis is generally considered to be irreversible." | ( Andrade, ZA; Cheever, AW; Dunn, MA; Duvall, RH; Goldner, FH; Kelly, EP; Paglia, LM, 1994) |
| "The severity of liver cirrhosis is an important factor for the occurrence of enhanced IL-8 levels." | ( Chen, LS; Hou, MC; Lee, FY; Lee, SD; Li, CP; Lin, HC; Lu, RH; Tsai, YT; Wang, SS; Wang, TF, 1996) |
| "The hallmark of liver fibrosis is an increased extracellular matrix deposition, caused by an activation of hepatic stellate cells (HSC)." | ( Beljaars, L; Bonnema, H; Groothuis, GM; Meijer, DK; Molema, G; Olinga, P; Poelstra, K; Weert, B, 1999) |
| "Hepatic cirrhosis is accompanied by several haemodynamic changes including arterialisation of the liver, intrahepatic shunts, pulmonary arteriovenous shunts, and a hyperdynamic circulatory state." | ( Albrecht, T; Blomley, MJ; Butler-Barnes, J; Cosgrove, DO; Eckersley, R; Jayaram, V; Patel, N; Taylor-Robinson, SD; Urbank, A, 1999) |
| "Patients with liver cirrhosis are at high risk of severe septic complications such as spontaneous bacterial peritonitis (SBP) and bacteraemia." | ( Aussel, C; Bories, PN; Campillo, B; Devanlay, M; Pernet, P; Richardet, JP, 1999) |
| "Patients with liver cirrhosis are insulin-resistant and frequently glucose-intolerant." | ( Arai, K; Hori, M; Imano, E; Kanda, T; Matsuhisa, M; Motomura, M; Nakatani, Y; Yamasaki, Y, 1999) |
| "Many patients with liver cirrhosis are in a state of protein and energy malnutrition and require careful nutritional support." | ( Kato, M; Kato, T; Miwa, Y; Moriwaki, H; Muto, Y; Ohnishi, H; Okuno, M; Shiratori, Y; Tajika, M; Yasuda, I, 2000) |
| "Liver fibrosis is a serious complication of schistosomiasis infection, is associated with increased amounts of collagen and the collagen cross-link, pyridinoline." | ( Stone, PJ, 2000) |
| "The extent of liver fibrosis is an important prognostic factor in patients infected with hepatitis C virus." | ( Albrecht, J; Bedossa, P; Davis, GL; Esteban-Mur, R; Goodman, Z; McHutchison, J; Poynard, T, 2000) |
| "Ascites in liver cirrhosis is a symptom of advanced liver disease, and liver transplantation should always be considered in eligible patients." | ( Lööf, L; Prytz, H; Söderlund, C; Wallerstedt, S, 2001) |
| "Liver fibrosis is the main cause of death in the 20 millions individuals suffering from chronic schistosomosis." | ( Dessein, A; Ranque, S, 2001) |
| "Liver fibrosis is characterized by an excessive accumulation of extracellular matrix components, which lead to the impairment of the hepatic function." | ( Gil, A; Gómez-Capilla, JA; Pérez, MJ; Sánchez-Medina, F; Suárez, A, 2002) |
| "Liver fibrosis is an important prognostic factor in patients with hepatitis C." | ( Albrecht, J; Goodman, Z; Lindsay, K; Ling, MH; Manns, M; McHutchison, J; Poynard, T; Trepo, C, 2002) |
| "Human liver cirrhosis is commonly associated with increased fasting and glucose induced insulin concentrations." | ( Capristo, E; Gasbarrini, G; Greco, AV; Manco, M; Mari, A; Mingrone, G, 2002) |
| "Liver fibrosis is a prepathological state wherein damaged liver tissues in chronic liver diseases, such as hepatitis, are not repaired to normal tissues, but converted to fibrous tissue." | ( Kang, KW; Kim, CW; Kim, SG; Kim, YG, 2002) |
| "Liver fibrosis is characterized by a dramatic increase in the expression of type I collagen." | ( Breindl, M; Brenner, DA; Gillan, A; Reif, S; Rippe, RA; Scanga, A; Yang, L; Yata, Y, 2003) |
| "Liver fibrosis is the result from a relative imbalance between synthesis and degradation of matrix proteins." | ( Gressner, AM; Janoschek, N; van de Leur, E; Weiskirchen, R, 2004) |
| "However, liver fibrosis is a prolonged change both in gene expression and histopathological alterations." | ( Jiang, Y; Kang, YJ; Liu, J; Waalkes, M, 2004) |
| "Liver fibrosis is a common pathological process of chronic liver diseases." | ( Weng, H; Yao, L; Yao, ZM; Yu, T; Zhao, GP; Zhou, YJ, 2004) |
| "Liver fibrosis is the main pathological finding in schistosomiasis that occurs after many years of infection." | ( Alcantara, L; Carvalho, EM; Gonzalez, D; Gonzalez, T; Guerreiro, JB; Ho, JL; Neva, F; Passos, J; Porto, AF; Santos, SB, 2004) |
| "Liver fibrosis is characterized by increased synthesis, and decreased degradation, of extracellular matrix (ECM) within the injured tissue." | ( Bradford, BU; Brenner, DA; Brocks, B; Cheung, E; Cho, MS; Feirt, N; Hirth-Dietrich, C; Knorr, A; Kraft, S; Krebs, B; Lum, P; Mei, B; Ng, P; Pan, CQ; Parsons, CJ; Ramamoorthi, R; Roldan, G; Schauer, M; Tomkinson, A; Zahn, S, 2004) |
| "Resolution of liver fibrosis is associated with clearance of hepatic myofibroblasts by apoptosis; development of strategies that promote this process in a selective way is therefore important." | ( Green, K; Iredale, JP; Mann, DA; Marek, CJ; May, MJ; Meso, M; Millward-Sadler, H; Oakley, F; Wright, MC; Zhou, X, 2005) |
| "Liver fibrosis is an over-accumulation of extra-cellular matrix (ECM) and the hepatic stellate cell (Ito cell) play a central role in the pathogenesis of liver fibrosis." | ( Chang, DC; Chen, JC; Chen, MH; Hsieh, HY; Tsai, CC; Tu, DG; Wang, WC, 2005) |
| "Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases." | ( Bataller, R; Brenner, DA, 2005) |
| "Liver fibrosis is the consequence of chronic or repeated liver injury caused by hepatotoxic agents like alcohol and viruses, as well as immune and congenital metabolic disorders." | ( Chuang, JH; Tai, MH; Wang, PW, 2004) |
| "If liver cirrhosis is present in hemochromatosis, the overall risk of developing heptatocellular carcinoma is 20 times higher than in the normal population." | ( Eisold, M; Gehrke, S; Gugler, R; Stremmel, W, 2005) |
| "Liver fibrosis is the result of an unbalanced wound healing response to a chronic hepatic injury." | ( de Gouville, AC; Huet, S, 2006) |
| "However, liver cirrhosis is characterized by activation of the renin-angiotensin-aldosterone axis, which increases hepatic vascular resistance and is augmented or suppressed by diuretics or octreotide, respectively." | ( Economou, M; Kalambokis, G; Kosta, P; Papadimitriou, K; Tsianos, EV, 2006) |
| "Liver fibrosis is characterized by an activation of hepatic stellate cells (HSC)." | ( Abergel, A; Chassard, C; Darcha, C; Dechelotte, P; Dif, N; Gaillard-Martinie, B; Marcand-Sauvant, J; Rock, E; Sapin, V; Sauvant, P, 2006) |
| "Liver fibrosis is characterized by accumulation of extracellular matrix proteins synthesized by activated hepatic stellate cells (HSCs)." | ( Jiang, F; Parsons, CJ; Stefanovic, B, 2006) |
| "The induction of liver fibrosis is difficult in mice." | ( Gerceker, S; Gonzalez-Carmona, MA; Guetgemann, I; Kornek, M; Ocker, M; Rabe, C; Raskopf, E; Sauerbruch, T; Schmitz, V, 2006) |
| "Severe liver fibrosis is common in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who have a high alanine aminotransferase (ALT) level." | ( Alvarez, E; Alvarez, F; Berenguer, J; Carlos Lopez, J; Cosin, J; Gutierrez, I; Miralles, P; Pilar, C; Ramirez, M; Sánchez-Conde, M, 2006) |
| "Liver fibrosis is usually progressive, but it can occasionally be reversible if the causative agents are adequately removed or if patients are treated effectively." | ( Higashiyama, R; Hong, YY; Inagaki, Y; Kushida, M; Matsuzaki, Y; Nakao, S; Niioka, M; Okano, H; Okazaki, I; Shiota, G; Watanabe, T, 2007) |
| "Liver fibrosis is the final common pathway in a variety of liver diseases." | ( Herkel, J; Lohse, AW; Weiler-Normann, C, 2007) |
| "Patients who have liver cirrhosis are at increased risk of bacterial infections, such as bacteremia, meningitis, pneumonia, urinary tract infections, and spontaneous bacterial peritonitis, due to immunodeficiency associated with the severity of the cirrhosis." | ( Chen, IY; Chung, CL; Howng, SL; Kwan, AL; Lieu, AS, 2007) |
| "Evaluation of liver fibrosis is important in the management of patients with genotype 3a hepatitis C, since it helps to predict response to IFN/RBV therapy." | ( Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG; Soffredini, R, 2006) |
| "Liver fibrosis is the result of an imbalance between synthesis and degradation of extracellular matrix proteins of the liver." | ( Li, DJ; Liang, ZP; Shen, ZY; Yang, Z; Zang, YJ; Zou, WL, 2007) |
| "Patients with liver cirrhosis are likely to be susceptible to tuberculosis (TB) because of immune system dysfunction." | ( Cho, YJ; Han, SK; Kim, YW; Lee, SM; Shim, YS; Yim, JJ; Yoo, CG, 2007) |
| "Advanced liver cirrhosis is associated with hyperdynamic circulation consisting of systemic hypotension, decreased peripheral resistance, and cardiac dysfunction, termed cirrhotic cardiomyopathy." | ( Bátkai, S; Harvey-White, J; Kechrid, R; Kunos, G; Mukhopadhyay, P; Pacher, P, 2007) |
| "Liver fibrosis is a result of disturbed balance between extracellular matrix protein synthesis and degradation." | ( Janczewska-Kazek, E; Kajdaniuk, D; Magiera, M; Marek, B; Pisula, A; Witor, A, 2007) |
| "Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications: portal hypertension, liver failure, hepatic encephalopathy, and hepatocellular carcinoma and others." | ( Armendáriz B, J; Gálvez G, J; García B, L, 2007) |
| "1." | ( Chen, M; Hu, XL; Wang, H; Xu, D, 2008) |
| "Liver fibrosis is associated with proliferation of hepatic stellate cells (HSCs) and their transformation into myofibroblastic cells that synthesize scar tissue." | ( Beljaars, L; Hagens, WI; Julien, B; Lotersztajn, S; Mann, DA; Poelstra, K; Reker-Smit, C; Wright, MC, 2008) |
| "Because its role in liver fibrosis is unknown, we studied alphavbeta6 function in vitro and explored the antifibrotic potential of the specific alphavbeta6 antagonist EMD527040." | ( Goodman, SL; Jonczyk, A; Patsenker, E; Popov, Y; Schuppan, D; Stickel, F, 2008) |
| "Liver fibrosis is characterized by an excess of collagen fiber deposition, and it is known that Kupffer cells play an important role by immunomodulation of the toxic response." | ( Galicia-Moreno, M; Moreno, MG; Muriel, P; Reyes-Gordillo, K; Rodríguez-Rivera, A; Segovia, J; Shibayama, M; Tsutsumi, V; Vergara, P, 2008) |
| "Diabetes in liver cirrhosis is associated with a blunted insulin response, which might be explained by an impaired release of the incretin hormone glucagon-like peptide 1 (GLP-1) into the portal circulation." | ( Buchwald, A; Leonhardt, U; Nolte, W; Raddatz, D; Ramadori, G; Rossbach, C; Scholz, KH, 2008) |
| "Liver fibrosis is characterized by high expression of the key profibrogenic cytokine transforming growth factor (TGF)-beta and the natural tissue inhibitor of metalloproteinases (TIMP)-1, leading to substantial accumulation of extracellular matrix." | ( Dagdelen, T; Eisele, S; Erben, U; Freise, C; Jia, J; Kim, K; Ruehl, M; Somasundaram, R; Stickel, F; Trowitzsch-Kienast, W; Zeitz, M, 2009) |
| "Decompensated liver cirrhosis is characterized by activation of the renin-angiotensin-aldosterone system (RAAS)." | ( Boomsma, F; Danser, AH; de Man, R; Kuiper, JJ; van Buren, H; van den Meiracker, AH, 2008) |
| "Liver fibrosis is a common scarring response to all forms of chronic liver injury and is always associated with inflammation that contributes to fibrogenesis." | ( Gao, B; Gershwin, ME; Jeong, WI; Lian, ZX; Park, O; Wang, H; Wang, L, 2009) |
| "Liver fibrosis is a consequence of the activation of hepatic stellate cells (HSCs), which reside within the extracellular matrix (ECM) of subsinusoids." | ( Gieling, RG; Han, YP; Wallace, K, 2009) |
| "Liver fibrosis is characterized by the excessive accumulation of extracellular matrix (ECM)." | ( Jo, JH; Kim, KH; Kim, SJ; Lee, WR; Park, JB; Park, JH; Park, KK, 2009) |
| "Liver fibrosis is regulated by an epigenetic relay pathway that includes MeCP2, EZH2, and miR132." | ( Chu, DC; Mann, DA; Mann, J; Maxwell, A; Oakley, F; Tsukamoto, H; Zhu, NL, 2010) |
| "Liver fibrosis is the result of continuous liver injury stemming from different etiological factors." | ( del Pilar Alatorre-Carranza, M; Delgado-Rizo, V; Fafutis-Morris, M; Hermosillo-Sandoval, JM; Hernández-Hoyos, S; Martínez-Abundis, R; Miranda-Díaz, A; Pizano-Martínez, O; Segura-Ortega, J; Vázquez-Del Mercado, M; Yañez-Sánchez, I, 2009) |
| "Liver fibrosis is one of the major health problems worldwide." | ( Menon, VP; Rajagopalan, R; Sridharana, S, 2010) |
| "Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs)." | ( de Meijer, VE; Le, HD; Meisel, JA; Nosé, V; Popov, Y; Puder, M; Schuppan, D; Sverdlov, DY, 2010) |
| "Severe liver fibrosis is a rare event in patients treated with MTX and is probably unrelated to the total dose." | ( Chabrun, E; de Lédinghen, V; Doutre, MS; Laharie, D; Longy-Boursier, M; Pellegrin, JL; Schaeverbeke, T; Seneschal, J; Villars, S; Zerbib, F, 2010) |
| "Liver fibrosis is a consequence of chronic liver disorders which lead to the accumulation of extracellular matrix (ECM)." | ( Jackson, JS; Mahato, RI; Panakanti, R; Pratap, A; Yang, N, 2010) |
| "Liver fibrosis is closely associated with the progression of various chronic liver diseases." | ( Iha, M; Nagamine, T; Nakazato, K; Takada, H, 2010) |
| "Liver fibrosis is orchestrated by a complex network of signaling pathways regulating the deposition of extracellular matrix proteins during fibrogenesis." | ( Bettermann, K; Castoldi, M; Janssen, J; Knolle, P; Koppe, C; Luedde, T; Roderburg, C; Schmidt, S; Tacke, F; Trautwein, C; Urban, GW; Vucur, M; Zimmermann, H, 2011) |
| "Liver fibrosis is accompanied by the loss of E-cadherin (ECAD), which promotes the process of epithelial-mesenchymal transition." | ( Anderson, RA; Cho, IJ; Han, CY; Hwang, SJ; Kim, EH; Kim, SG; Kim, YW; Lee, CH; Lee, YS, 2010) |
| "Liver fibrosis is characterized by excessive accumulation of the extracellular matrix (ECM) proteins." | ( Collighan, R; Daneshpour, N; Griffin, M; Perrie, Y, 2011) |
| "Liver fibrosis is an active process that involves changes in cell-cell and cell-extracellular matrix (ECM) interaction." | ( Alaniz, L; Aquino, JB; Atorrasagasti, C; Benedetti, L; Friedman, SL; Garcia, M; Hofman, L; Malvicini, M; Mazzolini, G; Podhajcer, O, 2011) |
| "Mechanisms of liver fibrosis are complex and varied." | ( Anty, R; Lemoine, M, 2011) |
| "Risk of liver fibrosis is increased in HIV-1/HCV coinfection and associated with reduced CD4 T-cell counts and raised lipopolysaccharide levels and/or depletion of hepatic Kupffer cells." | ( Kelleher, P; Nelson, M; Page, EE, 2011) |
| "Patients with HCV liver cirrhosis are a category difficult to treat." | ( Bota, S; Danila, M; Neghina, AM; Popescu, A; Sirli, R; Sporea, I; Strain, M, 2011) |
| "Liver fibrosis is a major health problem that can lead to the development of liver cirrhosis and hepatocellular carcinoma." | ( Abdalla, AM; Abdelwahab, SA; Mahmoud, AM; Mahmoud, ME; Morsy, MA, 2012) |
| "Liver fibrosis is a worldwide clinical issue." | ( Dou, K; Li, Y; Liu, X; Shi, M; Wang, D; Wang, X; Wu, L; Xia, N; Yang, J; Yao, L; Zhang, H; Zheng, J, 2011) |
| "Liver fibrosis is associated with angiogenesis and leads to portal hypertension." | ( DuPont, HL; Huebert, RC; Jagavelu, K; Jiang, ZD; Shah, VH; Simonetto, DA; Zhu, Q; Zou, L, 2012) |
| "Liver fibrosis is caused by chemicals or viral infection." | ( Iwasaki, N; Komatsu, Y; Ono, W; Waku, T; Yamaguchi, C; Yanagisawa, J, 2012) |
| "Liver fibrosis is a major cause of liver failure, but treatment remains ineffective." | ( He, RH; Huang, XR; Lan, HY; Meng, XM; Tan, JJ; Tang, LX; Yang, G; Zhou, L, 2012) |
| "Liver fibrosis is a major health problem worldwide and poses a serious obstacle for cell based therapies." | ( Ali, G; Khan, M; Khan, SN; Mohsin, S; Nasir, GA; Riazuddin, S; Shams, S, 2012) |
| "The severity of liver fibrosis is known to be a good indicator for surveillance, and for determining the prognosis and optimal treatment of non-alcoholic steatohepatitis (NASH)." | ( Aoki, K; Bando, Y; Enomoto, H; Kanehara, H; Kasayama, S; Koga, M; Nakamura, H; Nakasho, K; Nishiguchi, SH; Notsumata, K; Tanaka, N; Toya, D, 2012) |
| "Liver fibrosis is one of the rare disorders exhibiting the increased ATX and LPA levels in the blood." | ( Ikeda, H; Yatomi, Y, 2012) |
| "Liver fibrosis is characterized by the deposition and increased turnover of extracellular matrix." | ( Chalupsky, K; Ehrmann, J; Gregor, M; Hajduch, M; Jirkovska, M; Jirouskova, M; Sarnova, L; Sedlacek, R; Zbodakova, O, 2012) |
| "Liver fibrosis is a major cause of hepatic dysfunction and cancer and there are few effective therapies emphasizing the need for new approaches to control." | ( Al-Olayan, EM; Hassan, ZK, 2012) |
| "Liver fibrosis is commonly associated with obesity and most obese patients develop hyperleptinaemia." | ( Chen, H; Fan, J; Niu, M; Yan, K; Zhai, X; Zhou, Q; Zhou, Y, 2013) |
| "Liver fibrosis is the result of chronic liver injury, and it represents a widespread medical problem." | ( Blažeković, B; Domitrović, R; Jakovac, H; Marchesi, VV, 2013) |
| "Liver fibrosis is associated with infiltrating immune cells and activation of hepatic stellate cells." | ( Berres, ML; Fischer, P; Heinrichs, D; Nellen, A; Sahin, H; Scholten, D; Trautwein, C; Wasmuth, HE, 2013) |
| "Liver fibrosis is the excessive accumulation of extracellular matrix (ECM) proteins including collagen that occurs in most types of chronic liver diseases." | ( Atta, HM; Azzam, M; Motawi, TM; Sadik, NA, 2014) |
| "Liver fibrosis is an established determinant of prognosis and therapy in chronic hepatitis B (CHB)." | ( Acharya, SK; Das, P; Datta Gupta, S; Dhingra, R; Goyal, R; Kedia, S; Mahanta, M; Mallick, SR; Panda, S; Sharma, H, 2013) |
| "Liver fibrosis is a severe, life-threatening clinical condition resulting from nonresolving hepatitis of different origins." | ( Chen, C; Jiang, R; Liu, Q; Qian, X; Ryffel, B; Sun, B; Tan, Z; Wang, X; Wang, Y, 2013) |
| "Resolution of liver fibrosis is an emerging field in hepatology; yet, the mediators involved remain elusive." | ( Fiel, MI; Kitamura, N; Leung, TM; Nieto, N; Wang, X, 2013) |
| "Advanced liver fibrosis is a recognized barrier to both access and response to triple therapy with protease inhibitors Boceprevir and Telaprevir, and is associated with an increased risk of severe treatment-related adverse events." | ( Colombo, M; D'Ambrosio, R, 2013) |
| "1." | ( Lin, Y; Su, X; Wang, Y; Yang, X; Yu, R; Zheng, C; Zhou, G, 2014) |
| "Liver fibrosis is a reversible wound-healing response that occurs following liver injury." | ( Bahcecioglu, IH; Demiroren, K; Dogan, Y; Ilhan, S; Kocamaz, H; Ozercan, IH; Ustundag, B, 2014) |
| "The degree of liver fibrosis is strongly associated with the antiviral effect of interferon on chronic hepatitis C patients." | ( Harada, N; Hayashi, N; Hiramatsu, N; Kanto, T; Miyagi, T; Miyazaki, M; Morishita, N; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y, 2014) |
| "Since ConA-induced liver fibrosis is caused by the repeated activation of T cells, immunomodulatory substances might be responsible for the suppressive effect of HF." | ( Gao, MH; Li, Y; Li, YY; Liang, J; Liu, JB; Shen, RW; Zhang, B; Zhang, W, 2013) |
| "Extent of liver fibrosis is one of the most important factors in determining prognosis and the need for active treatment in chronic hepatitis B (CHB)." | ( Brcic, M; Hauser, G; Jovanovic, P; Salkic, NN, 2014) |
| "Several hallmarks of liver fibrosis are influenced by S1P, and the interference of S1P signaling by treatment with FTY720 results in beneficial effects in various animal models of fibrosis." | ( Kong, Y; Tang, N; Wang, H; Wang, S, 2014) |
| "Liver fibrosis is a common response to liver injury and, in severe cases, leads to cirrhosis." | ( Bohanon, FJ; Ding, C; Ding, Y; Radhakrishnan, GL; Radhakrishnan, RS; Rastellini, C; Wang, X; Zhou, J, 2014) |
| "Liver fibrosis is a common pathway leading to cirrhosis and a worldwide clinical issue." | ( Chen, K; Cheng, P; Chengfen, W; Dai, W; Guo, C; He, L; Li, J; Lu, J; Shen, M; Wang, F; Xu, L; Yang, J; Zhang, H; Zhang, Y; Zheng, Y; Zhou, Y; Zhu, R, 2014) |
| "Progressive liver fibrosis is characterized by the deposition of collagen by activated hepatic stellate cells (HSCs)." | ( Aroonsakool, N; Brenner, DA; De Minicis, S; Dunkel, Y; Ghosh, P; Ho, SB; Lopez-Sanchez, I; Mittal, Y; Muranyi, A; Murray, F; Roh, YS; Seki, E; Shanmugam, K; Singh, S, 2014) |
| "Cholestatic liver fibrosis is characterized by excessive collagen production and deposition, which is mediated by reactive oxygen species (ROS)." | ( Ale-Ebrahim, M; Eidi, A; Mortazavi, P; Tavangar, SM; Tehrani, DM, 2015) |
| "Hepatic cirrhosis is the final stage of liver dysfunction, characterized by diffuse fibrosis, which is the main response to the liver injury." | ( Kang, X; Liu, Y; Meng, M; Yang, Y; Zhang, H; Zhao, Z, 2015) |
| "Liver fibrosis is mediated by hepatic stellate cells (HSCs), which respond to a variety of cytokine and growth factors to moderate the response to injury and create extracellular matrix at the site of injury." | ( Bahrami, AJ; Campbell, JS; Gunaje, JJ; Hayes, BJ; Kenerson, HL; Mahoney, WM; Riehle, KJ; Stempien-Otero, AS; Yeung, RS, 2014) |
| "The goal of imaging liver cirrhosis is the early identification of high-grade dysplastic nodules/early HCC since their treatment is associated with a higher chance of radical cure and lower recurrence rates." | ( Ascanio, S; Garzillo, G; Golfieri, R; Renzulli, M, 2014) |
| "Liver fibrosis is a complex disease in which several pathological processes, such as inflammation and angiogenesis, are closely integrated." | ( Chang, HH; Chang, YS; Huang, TH; Lee, TY; Wen, CK, 2014) |
| "Liver fibrosis is a reversible wound-healing response that occurs following liver injury." | ( Ding, J; Liu, CM; Ma, JQ; Zhang, L, 2015) |
| "Liver fibrosis is characterized by excessive accumulation of extracellular matrix." | ( Fujita, M; Ichinose, A; Ito, C; Matsuyama, A; Morita, M; Naba, K; Okura, H; Soeda, M, 2015) |
| "Liver fibrosis is a pathological condition in which chronic inflammation and changes to the extracellular matrix lead to alterations in hepatic tissue architecture and functional degradation of the liver." | ( Bettaieb, A; Chiamvimonvat, N; Dong, H; Haj, FG; Hammock, BD; Harris, TR; Kodani, S; Myers, R, 2015) |
| "Hepatic cirrhosis is associated with abnormal red blood cell morphology and function, particularly impaired red blood cell deformability." | ( Anzai, K; Arase, Y; Hirose, S; Kagawa, T; Matsuzaki, S; Mine, T; Shiraishi, K; Tsuruya, K, 2015) |
| "Liver fibrosis is the excessive accumulation of extracellular matrix proteins that occurs in most chronic liver diseases." | ( Arauz, J; Favari, L; Flores-Beltrán, RE; Muriel, P; Rivera-Espinoza, Y; Shibayama, M, 2015) |
| "Liver fibrosis is scar tissue resulting from an uncontrolled wound-healing process in response to chronic liver injury." | ( Faber, KN; Heegsma, J; Laliena, A; Moshage, H; Shajari, S; Tuñón, MJ, 2015) |
| "Patients with liver cirrhosis are known to be immunocompromised hosts due to the dysfunction of the cellular and humoral immune systems, allowing easier bacterial translocation from the intestine to the systemic circulation via the portal vein." | ( Abe, H; Arita, M; Kamimura, K; Kawai, H; Kobayashi, M; Kobayashi, Y; Kumaki, D; Kusama, F; Mizuno, K; Ogawa, K; Sato, Y; Shinagawa, Y; Takahashi, Y; Takeuchi, M; Terai, S; Yamagiwa, S, 2015) |
| "Liver fibrosis is an integral stage in the development of chronic liver disease, and transforming growth factor β (TGFβ) is known to play a central role in the progression of this entity." | ( Fukuda, N; Fukushima, A; Inami, M; Matsumoto, Y; Moriyama, M; Soma, M; Tsunemi, A; Ueno, T; Yamada, T, 2015) |
| "Liver fibrosis is strongly associated with chronic inflammation." | ( Baligar, P; Kochat, V; Mukherjee, S; Mukhopadhyay, A; Rastogi, A, 2016) |
| "Liver fibrosis is a feature in the majority of chronic liver diseases and oxidative stress is considered to be its main pathogenic mechanism." | ( Bi, XY; Fang, RT; Luo, AL; Ren, GX; Wei, XL; Yang, YH; Zang, WJ; Zhao, M, 2015) |
| "Liver fibrosis is a pathological consequence of chronic liver diseases and results from the progressive accumulation of altered extracellular matrix, highly enriched in type I and III fibrillar collagens." | ( Bertran, E; Crosas-Molist, E; Fabregat, I, 2015) |
| "Liver fibrosis is a wound-healing response to chronic liver injury that results in the accumulation of extracellular matrix proteins." | ( Ding, J; Fu, R; Hong, L; Sun, Q; Wu, J; Xu, T; Zhang, H, 2016) |
| "Liver fibrosis is the consequence of diverse liver injuries and can eventually develop into liver cirrhosis." | ( Peng, R; Wang, R; Wang, Y; Wu, Y; Yuan, Y, 2015) |
| "Liver fibrosis is characterized by excessive deposition of extracellular matrix, which is induced by TGFβ signaling, and activated ERK is known to induce the phosphorylation of SMAD, thereby inhibiting TGFβ signaling." | ( Ahn, J; Hong, SS; Jung, KH; Kim, GJ; Kim, K; Lee, SH; Park, SG; Son, MK, 2016) |
| "Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma." | ( Byun, Y; Eom, H; Gao, B; Hahn, SK; Hamilton, JP; Hanes, J; Jeon, OC; Jo, DG; Kechrid, R; Kim, K; Kim, TH; Lee, CE; Lee, KC; Lee, S; Lim, SM; Mastorakos, P; Oh, Y; Park, JS; Park, O; Pomper, MG; Swierczewska, M; Zhang, C, 2016) |
| "Liver fibrosis is associated with significant collagen-I deposition largely produced by activated hepatic stellate cells (HSCs); yet, the link between hepatocyte damage and the HSC profibrogenic response remains unclear." | ( Antoine, DJ; Arriazu, E; Ge, X; Kitamura, N; Leung, TM; Lopategi, A; Lu, Y; Magdaleno, F; Nieto, N; Theise, N; Urtasun, R, 2017) |
| "Pregnancy with liver cirrhosis is a rare and dangerous event that exposes mother and fetus to potentially lethal risks." | ( Braga, A; Braga, J, 2016) |
| "Decompensated liver cirrhosis is an important cause of mortality worldwide." | ( Kumar, R; Noor, MT; Tiwari, M, 2016) |
| "Liver fibrosis is one of the most serious consequences of S." | ( Abdelsalam, RM; Attia, YM; El-Khatib, AS; Elkhafif, N; Elmazar, MM; Hammam, OA; Kenawy, SA; Mansour, MT, 2016) |
| "Liver fibrosis is present in both congenital biliary atresia and neonatal hepatitis patients." | ( Gao, ZG; Gu, WZ; Huang, SJ; Li, FB; Peng, KR; Shu, XL; Tou, JF; Zhao, H, 2016) |
| "Liver fibrosis is one of the major causes of morbidity and mortality worldwide and lacks efficient therapy." | ( Chen, DZ; Chen, RC; Chen, YP; Dong, JJ; Du, SJ; Feng, WK; Huang, SS; Liang, G; Wang, XD; Wu, H; Xu, LM; Yang, YP; Yu, ZP, 2016) |
| "Liver fibrosis is the principal cause of morbidity and mortality in patients with iron overload." | ( Chang, Y; Chu, L; Chu, X; Gao, Y; Guo, H; Liu, Z; Wang, N; Zhang, J; Zhang, X; Zhang, Y; Zhao, X, 2016) |
| "Liver fibrosis is the progressive accumulation of connective tissue ultimately resulting in loss of organ function." | ( de Jong, KP; Groothuis, GM; Hadi, M; Luangmonkong, T; Mutsaers, HA; Olinga, P; Oosterhuis, D; Westra, IM, 2016) |
| "Liver fibrosis is a worldwide problem with a significant morbidity and mortality." | ( He, YH; Huang, C; Li, J; Li, MF; Li, Z; Meng, XM; Ni, MM; Zhang, XY, 2016) |
| "Liver fibrosis is the common response to chronic liver injury and ultimately leads to cirrhosis." | ( Akhtar, M; Arora, I; Javed, K; Rastogil, S; Samim, M; Verma, SK, 2016) |
| "Liver fibrosis is characterized by significant accumulation of extracellular matrix (ECM) proteins, mainly fibrillar collagen-I, as a result of persistent liver injury." | ( Arriazu, E; Chen, Y; Conde de la Rosa, L; Ge, X; Magdaleno, F; Nieto, N; Ruiz de Galarreta, M, 2016) |
| "Liver fibrosis is a major pathological feature of chronic liver diseases, including liver cancer." | ( Hyun, J; Jung, Y; Kim, J; Lee, HH; Park, J; Seo, YS; Wang, S, 2016) |
| "Liver fibrosis is a reversible wound-healing process that is protective in the short term, but prolonged fibrotic responses lead to excessive accumulation of extracellular matrix components that suppresses hepatocyte regeneration, resulting in permanent liver damage." | ( Harpavat, S; Kim, KH; Lee, JM; Moore, DD; Zhou, Y, 2016) |
| "Liver fibrosis is concomitant with monocyte infiltration, which has been highlighted as novel therapeutic targets for chronic liver diseases." | ( Chen, J; Huang, R; Liu, Y; Pan, Z; Sun, Z; Wang, G; Wang, J; Wu, C; Wu, H; Xia, J; Xiong, Y; Yan, X; Zhang, Z, 2016) |
| "Liver fibrosis is a consequence of chronic liver lesion, which can progress into liver cirrhosis even hepatocarcinoma." | ( Chen, QL; Dong, S; Hu, YY; Li, XY; Liu, P; Song, YN; Su, SB; Sun, Y; Wei, B, 2016) |
| "Liver fibrosis is associated with a decrease in FSAP expression but, to date, nothing is known about how this might be regulated." | ( Kanse, SM; Leiting, S; Martinez-Palacian, A; Muhl, L; Seidl, S, 2016) |
| "Liver fibrosis is one of the leading causes of morbidity and mortality worldwide with very limited therapeutic options." | ( El-Agroudy, NN; El-Demerdash, E; El-Naga, RN; El-Razeq, RA, 2016) |
| "Liver fibrosis is a wound-healing response characterized with the accumulation of extracellular matrix (ECM)." | ( Chen, P; Gan, R; Guo, C; Huang, J; Huo, Y; Li, J; Lu, J; Wan, L; Yang, Q, 2016) |
| "Liver fibrosis is a pathological scarring response to chronic hepatocellular injury and hepatic stellate cells (HSCs) are key players in this process." | ( Caddeo, A; Dongiovanni, P; Lepore, SM; Mancina, RM; Meroni, M; Montalcini, T; Motta, BM; Pelusi, S; Pingitore, P; Pujia, A; Romeo, S; Rossi, G; Russo, C; Valenti, L; Wiklund, O, 2016) |
| "Liver fibrosis is a global health problem and previous studies have demonstrated that reactive oxygen species (ROS) play important roles in fibrogenesis." | ( Gao, Y; Gu, J; Kong, X; Sun, X; Wen, Y; Xia, Q; Yu, C; Yu, Y, 2016) |
| "Liver fibrosis is a reversible wound‑healing response to liver damage." | ( Cheng, C; Deng, L; Deng, X; Wang, P; Xu, K, 2016) |
| "Liver fibrosis is a progressive pathological process involving inflammation and extracellular matrix deposition." | ( Bertolino, P; Chowdhury, S; Cordoba, SP; Evans, KA; Gall, MG; Gorrell, MD; Holz, LE; Jolly, CJ; Levy, MT; McCaughan, GW; Polak, N; Vieira de Ribeiro, AJ; Wang, XM; Yao, TW; Yu, DM; Zheng, YZ, 2017) |
| "Liver fibrosis is a reversible wound-healing process aimed at maintaining organ integrity, and presents as the critical pre-stage of liver cirrhosis, which will eventually progress to hepatocellular carcinoma in the absence of liver transplantation." | ( He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY, 2016) |
| "Liver fibrosis is a reversible wound-healing response to any etiology of chronic hepatic injuries." | ( Cheng, J; Feng, S; Han, M; Li, Y; Li, Z; Liu, S; Lu, H; Tursun, K; Wang, Q; Zhang, Y, 2017) |
| "Liver fibrosis is the increasingly accumulation of extracellular matrix (ECM), caused by chronic liver injuries, and represents a difficult clinical challenge in the entire world." | ( Badea, O; Bejenaru, C; Bejenaru, LE; ChiriŢă, C; Ionică, FE; Mogoantă, L; Negreş, S; Nicola, GC; Popescu, NL; Turculeanu, A, 2016) |
| "Liver fibrosis is one of the major complications from upper right quadrant radiotherapy." | ( Abdel-Rafei, MK; Galal, SM; Hasan, HF, 2017) |
| "Liver fibrosis is now well recognized as the causative factor for increased mortality from complications associated with liver pathologies." | ( Chatterjee, S; Gajalakshmi, P; Majumder, S; Swaminathan, A; Viebahn, CS; Yeoh, GC, 2017) |
| "BACKGROUND Liver fibrosis is the result of chronic inflammation and repair, and many immune cells contribute to the process." | ( Bai, L; Chen, Y; Duan, Z; Lou, J; Zhang, X; Zheng, S, 2017) |
| "Liver fibrosis is the consequence of hepatocyte injury that leads to the activation of hepatic stellate cells (HSC)." | ( Abou-Elela, SH; Elmahdy, NA; Salem, ML; Sarhan, NI; Sokar, SS, 2017) |
| "Liver fibrosis is the most serious pathology caused by Schistosoma japonicum infection, which arises when schistosome eggs are deposited in the liver." | ( Chou, X; Fang, Z; Guan, F; Lei, J; Li, Y; Liu, W; Lu, S; Wang, Q, 2017) |
| "Although liver fibrosis is a major public health issue, there is still no effective drug therapy in the clinic." | ( Bi, Q; Huang, L; Li, C; Li, Z; Liu, S; Shen, Q; Xie, J, 2017) |
| "Liver fibrosis is a pathological process complicating schistosomiasis." | ( Ashour, RH; Elhenawy, AA; Megahed, N; Nabih, N; Shalaby, NM, 2017) |
| "Liver fibrosis is a global health problem and its relationship with imidazoline I2 receptor has not been reported." | ( Hao, C; Jianping, G; Xuanfei, L; Yanming, L; Zhujun, Y, 2017) |
| "Liver fibrosis is a major health problem." | ( Abdel-Naim, AB; Algandaby, MM; Ashour, OM; Breikaa, RM; Eid, BG; Neamatallah, TA, 2017) |
| "Hepatic cirrhosis is often accompanied by functional kidney impairment, which may be reversed if early treatment is promptly administered." | ( Feng, JF; Liu, YS; Wang, AQ; Wang, D; Yang, YW, 2017) |
| "Liver fibrosis is the main pathology of schistosomiasis and its complications are the major cause of death in infected cases." | ( Brakat, RM; Mohamed, ASED; Sharaf El-Deen, SA, 2017) |
| "Liver fibrosis is a worldwide clinical issue." | ( Hu, X; Li, J; Li, S; Lu, C; Qi, W; Yang, H; Zhang, M; Zong, Y, 2018) |
| "Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available." | ( Bigaeva, E; Boersema, M; de Jong, KP; Luangmonkong, T; Mutsaers, HAM; Olinga, P; Oosterhuis, D; Schuppan, D; Suriguga, S, 2017) |
| "Liver fibrosis is a pathological process that can escalate to cirrhosis and then liver failure, a major public health concern that affect hundreds of millions of people in both developed and developing countries." | ( Escobedo, G; González, FJ; Guzmán, C; Kershenobich, D; Kolosovas-Machuca, ES; Ramírez-Elías, MG, 2017) |
| "Liver fibrosis is the response of liver diseases that puzzles patients." | ( Guo, SL; Huang, A; Shao, M; Wen, W; Xu, HB; Xuan, J; Yang, Y, 2017) |
| "Liver fibrosis is the excessive accumulation of extracellular matrix proteins, which is mainly caused by accumulation of activated hepatic stellate cells (HSCs)." | ( Bu, S; Chang, N; Fan, J; Ghazwani, M; He, F; Huang, Y; Li, J; Li, L; Li, S; Liu, K; Ma, X; Xie, W, 2017) |
| "Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression." | ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017) |
| "Liver fibrosis is a multifaceted process that occurs as a consequence of chronic liver injury." | ( DI Maira, G; Marra, F; Pastore, M, 2018) |
| "Liver fibrosis is the outcome of chronic liver injury." | ( Alsamman, M; Kuscuoglu, D; Meurer, SK; Sahin, H; Schaeper, U; Scholten, D; Sterzer, V; Strnad, P; Trautwein, C; Weiskirchen, R, 2018) |
| "Liver fibrosis is a global health problem without approved treatment." | ( El-Hadidy, WF; El-Khatib, AS; El-Mezayen, NS; El-Refaie, WM; Khattab, MM; Shalaby, TI, 2017) |
| "Liver fibrosis is a common pathological feature of many chronic liver diseases." | ( Dai, R; Deng, Y; Ke, M; Liu, X; Meng, W; Suheryani, I, 2017) |
| "Liver fibrosis is a common stage in the majority of chronic liver diseases, regardless of the etiology, and its progression may lead to hepatic cirrhosis or hepatocellular carcinoma." | ( Jiang, H; Li, WP; Li, ZQ; Ma, R; Qin, XJ; Wang, T, 2017) |
| "Liver fibrosis is a pathological process of chronic liver diseases." | ( Cao, Y; Chu, Y; Li, H; Li, L; Liu, J; Shi, Y; Yuan, X; Zhang, Z; Zheng, J, 2018) |
| "Liver fibrosis is overly exuberant wound healing that leads to portal hypertension or liver cirrhosis." | ( Fan, X; Ge, S; He, J; Jia, R; Li, B; Li, P; Li, Y; Ma, X; Pan, H; Shang, Q; Wang, H; Wang, L; Yang, Z; Zhang, H; Zhu, L, 2018) |
| "Liver fibrosis is accelerated by unknown mechanisms in human immunodeficiency virus-1- (HIV-1-) coinfected individuals." | ( Jones, LR; Laufer, N; Manrique, JM; Parra, M; Quarleri, J, 2017) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "Liver fibrosis is a major health problem that has no satisfactory medication." | ( Abdallah, HM; Abdel-Naim, AB; Ahmed, OAA; Al-Sawahli, MM; Algandaby, MM; Ashour, OM; Fahmy, UA; Hattori, M, 2016) |
| "Liver fibrosis is a key factor to determine therapeutic interventions for patients with CHB." | ( Miranda, AS; Simões E Silva, AC, 2017) |
| "Liver fibrosis is a progressive pathological process that accompanies wound healing; however, therapeutics for reversing hepatic fibrosis are unavailable." | ( Cho, EH; Choi, DH; Le, CT; Park, SY; Sung, KY, 2018) |
| "Liver fibrosis is a progressive pathological process resulting in an accumulation of excess extracellular matrix proteins." | ( Bordukalo-Niksic, T; Brkljacic, J; Bubic-Spoljar, J; Dumic-Cule, I; Erjavec, I; Grgurevic, I; Grgurevic, L; Kufner, V; Matijasic, M; Novak, R; Paljetak, HC; Pauk, M; Plecko, M; Rogic, D; Verbanac, D; Vukicevic, S, 2017) |
| "Liver fibrosis is one of the most serious conditions affecting patients worldwide." | ( Agha, AM; Ahmed, LA; Mohamed, YS; Salem, HA, 2018) |
| "Liver fibrosis is an excessively reversible wound healing process and the fibrotic disorder is the activation of hepatic stellate cell that requires extensive alterations in gene expression." | ( Abdelghany, HM; El-Tahawy, NF; Ramzy, MM; Zenhom, NM, 2018) |
| "Liver fibrosis is a reversible wound-healing response that occurs after liver injury." | ( Chen, J; Gan, D; He, W; Huang, C; Li, B; Wang, A; Zhang, W; Zhu, X, 2018) |
| "Liver fibrosis is a major health issue leading to high morbidity and mortality." | ( Abd El-Rahman, SS; Abdel-Rahman, RF; Afifi, N; Fayed, HM; Ramadan, A; Yassin, NZ, 2018) |
| "Liver fibrosis is excessive accumulation of extracellular matrix proteins that results from various chronic liver diseases." | ( Guo, T; Liu, CH; Liu, ZL; Zhao, Q; Zhao, ZM, 2018) |
| "Liver fibrosis is a worldwide clinical challenge during the progression of chronic liver disease to liver cirrhosis." | ( Chen, K; Fan, X; Feng, J; Guo, C; Li, J; Li, S; Liu, T; Lu, X; Mo, W; Wang, C; Wang, W; Wu, L; Xia, Y; Xu, L; Xu, S; Zhao, Y; Zhou, Y, 2019) |
| "Liver fibrosis is the first step toward the progression to cirrhosis, portal hypertension, and hepatocellular carcinoma." | ( Lee, CY; Liao, YJ; Lin, FZ; Twu, YC; Wang, CK; Wang, YH, 2018) |
| "Liver fibrosis is an important process that occurs in most types of chronic liver diseases and often results in the end stage of liver diseases, such as cirrhosis, portal hypertension, and hepatocellular carcinoma." | ( Chen, Y; Dong, H; Liu, X; Ma, Z; Wang, L; Xia, D; Xiong, Y, 2018) |
| "Liver fibrosis is a reversible pathological condition, whereas cirrhosis, the end-stage of liver fibrosis, is irreversible." | ( Gao, Y; Ni, Y; Yin, W; Yuan, Y; Zhang, F, 2018) |
| "Liver fibrosis is commonly seen and a necessary stage in chronic liver disease." | ( Chen, K; Feng, J; Guo, C; Li, J; Li, S; Liu, T; Lu, X; Wang, W; Wu, L; Xia, Y, 2018) |
| "Liver fibrosis is the final common pathway for almost all causes of chronic liver injury." | ( Alves de Castro, I; Barbisan, LF; Cogliati, B; Crespo Yanguas, S; da Silva, TC; Gijbels, E; Goes, BM; Maes, M; Pereira, IVA; Romualdo, GR; Sayuri Nogueira, M; Shestopalov, VI; Vinken, M; Willebrords, J, 2018) |
| "Liver fibrosis is a common consequence of chronic liver diseases resulting from multiple etiologies." | ( Chen, ZN; Cheng, B; Guo, HW; Liang, YH; Liu, X; Liu, XW; Mo, YY; Ruan, JX; Song, FM; Song, H; Su, ZH; Tang, CL; Wu, F; Wu, JX; Yin, CL; Zheng, H; Zhu, HJ, 2018) |
| "TCA promoting liver cirrhosis is likely through activating hepatic stellate cells via upregulating TLR4 expression." | ( Chang, Q; Duan, Z; Guo, Q; Huang, M; Liu, B; Liu, Z; Sun, X; Zhang, Z, 2018) |
| "Liver fibrosis is problematic after persistent injury." | ( Amini-Nik, S; Belo, C; Diao, L; Jeschke, MG; Sadri, AR, 2018) |
| "Liver fibrosis is a chronic disease that exhibits a complicated pathophysiology." | ( Liu, F; Ma, Z; Qian, J; Wu, G; Zhang, J, 2018) |
| "Liver fibrosis is a worldwide health problem with no established therapy until now." | ( Eissa, LA; El-Karef, A; El-Mihi, KA; Elsherbiny, NM; Kenawy, HI, 2018) |
| "Liver fibrosis is a common symptom of non-alcoholic steatohepatitis (NASH) and a worldwide clinical issue." | ( Huang, K; Liu, X; Mei, D; Niu, Z; Zhang, B, 2019) |
| "Liver fibrosis is the underlying cause of cirrhosis and liver failure in any type of chronic liver injury." | ( Liu, J; Ma, Y; Wang, J; Zhang, J; Zhang, Y; Zhu, J, 2018) |
| "Liver fibrosis is a common pathological response to chronic hepatic injury." | ( Li, J; Long, J; Wang, Z; Xiao, W; Zhang, H, 2018) |
| "Liver fibrosis is a global health issue that causes morbidity and mortality with no currently available treatment." | ( Abdel-Rahman, N; El-Awady, MS; Megahed, N; Sharawy, MH, 2018) |
| "Liver fibrosis is significantly improved regardless of the response." | ( Abd Elfatah, AS; Abdalla, NH; Abdel-Raheim, S; Abdulghany, HM; Khairy, RM; Zenhom, NM, 2018) |
| "In conclusion, liver cirrhosis is associated with deterioration of renal functions." | ( Abd El Samad, AA; El-Kharashi, OA; El-Waseef, DAA; Magdy, YM; Nabih, ES, 2018) |
| "Liver fibrosis is characterized by excessive deposition of extracellular matrix (ECM) components and results in impaired liver function." | ( Du, J; Hou, S; Kang, Z; Wang, B; Wang, C; Xue, L; Zhang, C, 2018) |
| "Liver fibrosis is a serious threat to human health, and there is currently no effective clinical drug for treatment of the disease." | ( Chen, HY; Jiang, ZJ; Shen, QH; Shuai, MQ; Yang, Z; Zheng, SS, 2019) |
| "Liver fibrosis is a health concern that leads to organ failure mediated via production of inflammatory cytokines and fibrotic biomarkers." | ( Abdel-Salam, RM; Ahmed, NA; Mansour, HM; Salama, AAA; Yassen, NN; Zaki, HF, 2018) |
| "Liver fibrosis is characterized as excessive deposition of the extracellular matrix proteins, primarily by activated hepatic stellate cells (HSCs)." | ( Chen, H; Cummins, CB; Ding, Y; Hughes, BD; Radhakrishnan, RS; Wang, X; Xu, J; Zhou, J, 2018) |
| "Liver fibrosis is a common pathological response in chronic liver injury." | ( Gu, GX; Xia, Q; Zhang, WQ, 2018) |
| "Staging of liver fibrosis is critical in guiding the treatment of chronic hepatitis B (CHB) virus." | ( Gu, J; Hu, J; Li, L; Yang, M; Zhang, X; Zhao, H, 2019) |
| "Progressive liver fibrosis is the primary cause of liver cirrhosis and hepatocellular carcinoma, and leads to considerable morbidity and mortality." | ( Ma, J; Ma, L; Ou, HL, 2019) |
| "The process of liver fibrosis is reversible and involves a recovery phase." | ( Guo, R; Ke, S; Lin, M; Su, Z; Zeng, D, 2019) |
| "Liver fibrosis is characterised by excessive deposition of extracellular matrix that interrupts normal liver functionality." | ( Farnaud, SJ; Mehta, KJ; Sharp, PA, 2019) |
| "Liver fibrosis is a worldwide clinical issue." | ( Hao, M; Lu, T; Mao, C; Mao, J; Su, D; Wang, Q; Xie, H; Yu, M; Zhang, J, 2020) |
| "Liver fibrosis is featured with excessive deposition of extracellular matrix and fibrous connective tissue hyperplasia." | ( Jiang, H; Ma, J; Qiu, Y; Wang, M; Zhang, M; Zhao, X, 2019) |
| "Liver fibrosis is characterized by formation of scar tissue in the liver." | ( Choi, S; Jang, YS; Jung, HJ; Kang, JH; Kim, MW; Oh, SH; Shin, D; Yoon, YS, 2019) |
| "Liver fibrosis is a serious liver disease associated with high morbidity and mortality." | ( Fu, Y; Gong, T; Jia, M; Li, W; Luo, J; Yin, P; Zhang, P; Zhang, ZR; Zhao, T, 2019) |
| "Liver fibrosis is a chronic lesion which ultimately results in cirrhosis and possible death." | ( Gu, Y; Li, S; Song, F; Wang, R; Wang, Y; Wu, B; Yuan, Y, 2019) |
| "Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, which occurs in most types of chronic liver diseases." | ( Chang, CC; Chen, YC; Chung, YS; Chyan, YJ; Hsu, SL; Hsu, WH; Huang, CF; Huang, KW; Liao, SC; Siu, ML, 2019) |
| "Liver fibrosis is a progression of chronic liver disease with lacks effective therapies at present." | ( Chen, Q; Dahan, A; Tan, W; Wei, L; Xue, J; Zhang, G; Zhang, H, 2019) |
| "Liver fibrosis is a serious health problem which is a critical cause of morbidity and mortality worldwide." | ( Abdel-Bakky, MS; Abo-Saif, AA; Mahmoud, NI; Messiha, BAS; Salehc, IG, 2019) |
| "Liver fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) leading to impaired function and cirrhosis." | ( Agarwal, SK; Pedroza, M; Smith, J; To, S, 2019) |
| "Liver fibrosis is a common public health problem." | ( Huang, Q; Huang, S; Li, R; Ming, Z; Wang, M; Xu, T; Zhao, Y, 2019) |
| "Liver fibrosis is a wound-healing process of liver featured by the over-deposition of extracellular matrix (ECM) and angiogenesis." | ( Chen, J; Chen, K; Dai, W; Fan, X; Feng, J; Guo, C; Ji, J; Li, J; Li, S; Liu, T; Mao, Y; Wang, C; Wang, F; Wu, J; Wu, L; Yu, Q; Zhang, J; Zhou, Y, 2019) |
| "Liver fibrosis is a challenging global health problem resulting from chronic liver injury with no treatment currently available." | ( El-Awady, MS; Makled, MN; Sharawy, MH, 2019) |
| "Liver fibrosis is an important health problem without adequate and effective therapeutics." | ( Chen, C; Li, X; Wang, L, 2020) |
| "Liver fibrosis is the common pathological basis of all chronic liver diseases, and is the necessary stage for the progression of chronic liver disease to cirrhosis." | ( Jiang, HX; Liang, ZY; Qin, SY; Su, SB; Wang, F; Yan, YD; Zhangdi, HJ, 2019) |
| "Liver fibrosis is a leading cause of mortality worldwide." | ( Lemasters, JJ; Rockey, DC; Takemoto, K; Wimborne, HJ; Woster, PM; Zhong, Z, 2019) |
| "Liver fibrosis is a major cause of morbidity and mortality worldwide." | ( Chen, Y; Duan, Y; Han, J; Li, Q; Li, X; Wei, Z; Yang, X; Zeng, P; Zhang, S; Zhang, W; Zhang, Y; Zhao, D, 2019) |
| "Liver fibrosis is a pathophysiologic process involving the accumulation of extracellular matrix proteins as collagen deposition." | ( Brancaccio, M; Castellano, I; D'Argenio, G; Milito, A, 2019) |
| "Patients with liver cirrhosis are susceptible to gram-negative infection." | ( Hosokawa, N; Katayama, M; Yamamuro, R, 2020) |
| "Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and hepatocellular carcinoma." | ( Dewidar, B; Dooley, S; Meindl-Beinker, AN; Meyer, C, 2019) |
| "Liver fibrosis is a major pathological feature of chronic liver diseases, and effective therapies are limited at present." | ( Chen, X; Chen, Y; Wang, S; Yin, L; Zhang, Y; Zhao, P; Zhou, Y, 2020) |
| "Many patients of liver cirrhosis are complaining of muscle cramps, which are annoying to them." | ( Abd-Elsalam, S; Alkhalawany, W; Badawi, R; Ebrahim, S; Elfert, A; Elkadeem, M; Hawash, N; Soliman, S, 2020) |
| "Liver fibrosis is the hallmark of chronic nonalcoholic steatohepatitis (NASH) and is characterised by the excessive deposition of extracellular matrix proteins." | ( Boominathan, R; Cheng, P; Chong, YC; Deng, X; Goggi, JL; Han, W; Hartimath, SV; Robins, EG; Soh, V; Tan, PW; Yong, FF, 2019) |
| "Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%." | ( Bendtsen, F; Deshmukh, AS; Fred, RG; Grønbæk, H; Hansen, T; Kimer, N; Mann, M, 2020) |
| "Liver fibrosis is involved in the progression of most chronic liver diseases." | ( Cheng, ML; Cheng, Z; Cong, S; Fan, LD; Hu, YX; Lei, Y; Liu, YM; Mu, M; Yu, L; Zhang, BF; Zhao, XK; Zhu, LL, 2020) |
| "Liver fibrosis is a crucial pathological feature which could result in cirrhosis and hepatocarcinoma." | ( Hu, J; Qiao, M; Yang, J; Zhao, Y; Zhu, Y, 2020) |
| "Liver fibrosis is a pathological manifestation induced by chronic liver injury and may cause cirrhosis and liver cancer with the chronic progression of fibrosis." | ( Chen, G; Chen, J; He, X; Liu, P; Liu, W; Mu, Y; Zhang, H, 2020) |
| "Liver fibrosis is a serious chronic disease that developed by a coordinated interplay of many cell types, but the underlying signal transduction in individual cell type remains to be characterized." | ( Fan, Y; Ge, S; Huang, W; Ji, R; Liu, Z; Lu, C; Wei, J; Xiao, M; Zhang, J; Zhou, D, 2020) |
| "Liver fibrosis is a wound healing process in response to chronic liver injury, which is characterized by the accumulation of extracellular collagen produced by Hepatic Stellate Cells (HSCs)." | ( Haas, U; Hennings, J; Hübbers, A; Lambertz, D; Liedtke, C; Nevzorova, YA; Sonntag, R; Trautwein, C, 2020) |
| "Liver fibrosis is a major medical problem with high mortality and morbidity rates where the formation of regenerative nodules and cirrhosis leads to loss of liver function and may result in the development of hepatocellular carcinoma." | ( Abo-Elmatty, DM; El-Demerdash, RS; Elminshawy, HH; Khalil, MR; Mehanna, ET; Mesbah, NM, 2021) |
| "Liver fibrosis is a common part of the pathological development of many chronic liver diseases." | ( Cao, Z; Du, H; Fang, Y; Fu, J; Kuang, T; Lei, X; Li, C; Liu, G; Liu, Q; Liu, Z; Qian, K; Xiao, Z; Xu, X; Zhang, J, 2020) |
| "Liver fibrosis is a histological change that often occurs due to hepatic stellate cell (HSC) activation and excessive formation of an extracellular matrix in the liver." | ( Li, HT; Li, XX; Shi, YS; Zhang, Y, 2020) |
| "Liver fibrosis is a common complication of diabetes mellitus, with a major global public health concern." | ( Aboulmagd, YM; Azab, SS; El-Bahy, AAZ; El-Demerdash, E; Menze, ET, 2020) |
| "Liver fibrosis is an outcome of many chronic liver diseases and often results in cirrhosis, liver failure, and even hepatocarcinoma." | ( Cai, FF; Chen, QL; Lu, YY; Su, SB; Wu, R; Zhang, H; Zhou, WJ; Zhou, Y, 2021) |
| "Liver fibrosis is the reversible deposition of extracellular matrix (ECM) and scar formation after liver damage by various stimuli." | ( Huang, C; Liu, C; Luo, F; Luo, Q; Wan, S; Zhu, X, 2020) |
| "Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals (DAAs) and patient prognosis." | ( Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA, 2020) |
| "Liver fibrosis is characterized by the excessive accumulation of extracellular matrix proteins." | ( Choi, BK; Hur, YH; Katoch, N; Kim, HB; Kim, HJ; Kim, JW; Park, JA; Woo, EJ, 2021) |
| "Since liver cirrhosis is often associated with increased oxidative stress and decreased antioxidant capacities, we conducted a double-blind randomized controlled trial to assess the antioxidative effect of vitamin B-6, GSH, or vitamin B-6/GSH combined supplementation in cirrhotic patients." | ( Cheng, SB; Hsiao, YF; Huang, YC; Lai, CY; Lee, TY; Liu, HT, 2020) |
| "Liver fibrosis is a disease caused by long-term damage that is related to a number of factors." | ( Bai, J; Bi, Z; Li, H; Li, X; Ma, B; Ma, X; Ning, W; Shao, S; Wei, Y; Xie, C; Yang, C; Zhang, L; Zhang, R; Zhang, S; Zhou, H, 2020) |
| "Liver fibrosis is a pathological change existing in most chronic liver diseases, which leads to abnormal changes in liver tissue structure and affects the normal physiological function of liver." | ( Huang, J; Li, J; Lu, L; Luo, W; Ma, X; Tang, M; Zheng, J, 2020) |
| "Fatty liver and the liver fibrosis are known risk factors for cardiovascular disease (CVD)." | ( Chikamori, T; Fujii, M; Iwasaki, Y; Matsumoto, C; Nakano, H; Shiina, K; Tomiyama, H; Yamashina, A, 2021) |
| "Liver fibrosis is characterized by the transdifferentiation of hepatic stellate cells (HSCs) to myofibroblasts and poor response to treatment." | ( Fang, CH; Guo, CJ; Li, H; Pan, Q; Wang, JZ; Xu, QY, 2020) |
| "Significant liver fibrosis is uncommon among patients with Crohn's disease, even among those exposed to methotrexate." | ( Bargalló, A; Domènech, E; Garcia-Planella, E; Gely, C; Gordillo, J; Llaó, J; Mañosa, M; Masnou, H; Romero, C, 2021) |
| "Liver fibrosis is an increasing health problem worldwide, for which no effective antifibrosis drugs are available." | ( Chen, H; Chen, P; Cheng, G; Fan, J; He, L; Hong, J; Hu, K; Jiang, Y; Li, J; Lin, L; Lin, W; Lin, Z; Qu, C; Tu, M; Yuan, H; Zheng, D, 2020) |
| "Liver fibrosis is an inflammatory and fibrogenic process that occurs following chronic liver damage." | ( Moradi, A; Nozari, E; Samadi, M, 2020) |
| "Liver fibrosis is a multifactorial trait that develops in response to chronic liver injury." | ( Asaryan, A; Beaven, SW; Borawski, J; Cantor, RM; Carbone, W; Civelek, M; Clerkin, K; French, S; Fuqua, BK; Haroutunian, SG; Hui, ST; Knehr, J; Loureiro, J; Lusis, AJ; Magyar, C; Mehrabian, M; Pan, C; Parks, BW; Renaud, N; Roma, G; Tuominen, I; Ukomadu, C; Wroblewski, K, 2021) |
| "Liver fibrosis is defined as excessive extracellular matrix deposition in the hepatic parenchyma as a consequence of complex interactions among matrix-producing hepatic stellate cells (HSCs) and liver-resident and infiltrating cells." | ( Armeli Iapichino, EC; Bramanti, A; Bramanti, P; Ciurleo, R; Fagone, P; Magro, GG; Mangano, K; Nicoletti, F; Pesce, A; Petralia, MC, 2020) |
| "Liver fibrosis is a common process resulting from various etiologies." | ( Hu, Y; Li, Z; Liu, G; Ni, M; Wang, L; Wen, X; Yang, Y; Yu, H, 2021) |
| "Liver fibrosis is a common pathologic process related to chronic liver disease." | ( Li, MM; Li, XA; Nie, D; Zhou, Y; Zuo, L, 2021) |
| "Liver fibrosis is characterized by the extracellular matrix accumulation after hepatic injury and can lead to cirrhosis." | ( Borojevic, R; Coelho, BP; Costa, BP; de Oliveira, CM; de Oliveira, JR; de Sousa, AC; Guma, FCR; Martins, LAM; Moraes, KDS; Vieira, MQ, 2021) |
| "Liver fibrosis is a difficult problem in the medical field." | ( Cao, P; Chen, A; Gao, L; Li, Y; Shao, J; Tan, S; Wang, S; Wang, Z; Yang, X; Zhang, F; Zhang, Z; Zheng, S, 2021) |
| "Liver fibrosis is a wound healing response that arises from various aetiologies." | ( Cai, J; Chen, G; Chen, H; Du, C; Guan, Y; Jiang, C; Liu, Q; Pan, L; Qiu, D; Qiu, Y; Wang, J; Wang, Y; Xiang, AP; Xu, Y; Yang, Y; Yi, C; Zhang, Q; Zheng, J, 2021) |
| "Liver fibrosis is a reversible wound-healing response to acute or chronic liver injury that can progress to cirrhosis and liver cancer." | ( Chen, Y; Deng, H; Liu, J; Liu, X; Wang, N; Wang, Q; Yang, C; Zhang, W; Zong, Z, 2021) |
| "Liver fibrosis is characterized by the accumulation of extracellular matrix proteins, mainly composed of collagen." | ( Bank, R; de Meijer, VE; de Waart, DR; Faber, KN; Fagundes, RR; Gomez, V; Heegsma, J; Kong, D; Olinga, P; Paulusma, CC; Smith-Cortinez, N; Sydor, S; Taylor, CT, 2021) |
| "Liver fibrosis is the excessive accumulation of extracellular matrix proteins that occurs in chronic liver disease." | ( Alonso, C; Aloria, K; Arizmendi, JM; Avila, MA; Azkargorta, M; Banales, JM; Barrio, R; Beraza, N; Bizkarguenaga, M; Delgado, TC; Elortza, F; Fernández-Ramos, D; Goikoetxea-Usandizaga, N; Juan, VG; Lachiondo-Ortega, S; Lectez, B; Lopitz-Otsoa, F; Lozano, JJ; Marin, JJG; Martínez-Chantar, ML; Mato, JM; Mayor, U; Mercado-Gómez, M; Rodríguez-Agudo, R; Serrano-Maciá, M; Simon, J; Sutherland, JD, 2020) |
| "Liver fibrosis is a complex process associated to most types of chronic liver disease, which is characterized by a disturbance of hepatic tissue architecture and the excessive accumulation of extracellular matrix." | ( Castillo, I; Donoso, W; González, DR; Herrera, F; Orrego, R; Rodríguez, MJ; Zúñiga-Hernández, J, 2020) |
| "Liver fibrosis is associated with poor liver-related outcomes and mortality." | ( Bendtsen, F; Benfield, T; de Knegt, RJ; Kirkegaard-Klitbo, DM; Kofoed, KF; Lundgren, J; Nielsen, SD, 2021) |
| "Liver fibrosis is inevitable in the healing process of liver injury." | ( Guan, W; Lai, J; Lu, H; Sun, Y; Wu, X; Zhang, S, 2020) |
| "Liver fibrosis is a debilitating disease threatening human health." | ( Bai, Y; Chen, G; Liu, C; Lu, Z; Ma, L; Shi, R; Wang, F; Wang, L; Wang, W; Xu, Q; Zhai, D, 2021) |
| "Liver fibrosis is a necessary stage in the development of chronic liver diseases to liver cirrhosis." | ( Cheng, P; Guo, C; Wu, J; Yu, Q, 2021) |
| "Liver fibrosis is a chronic liver injury that leads to liver cirrhosis and liver cancer." | ( Chen, S; Dai, X; Gong, Y; Huang, H; Li, H; Zhao, Y, 2021) |
| "Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it." | ( Chen, M; Gu, J; Guo, X; He, D; Hu, L; Kuang, M; Liu, B; Ruan, Y; Wu, H; Zeng, X, 2021) |
| "Liver fibrosis is characterized by excess accumulation of extracellular matrix in response to chronic injury." | ( Dong, X; Lu, S; Luo, Y; Ma, H; Sun, G; Sun, X; Zhang, W; Zhu, Y, 2021) |
| "Liver fibrosis is the result of an excessive accumulation of extracellular matrix that develops when inflammation and chronic injury form scar tissue in the liver." | ( A M Alameen, A; Alzahrani, B; Tantawy, A, 2021) |
| "Liver fibrosis is a critical health issue in the world due to its rapidly increasing prevalence." | ( Chen, L; Lin, YH; Liu, M; Tang, SG; Tong, M; Zheng, Q; Zhu, YM, 2021) |
| "Liver fibrosis is a public health burden that is highly associated with morbidity and mortality." | ( El-Awady, MS; Makled, MN; Sharawy, MH, 2021) |
| "Liver fibrosis is a final result of extensive deposition of extracellular matrix (ECM) and starts with the activation and proliferation of hepatic stellate cells (HSCs)." | ( Chen, JJ; Geng, CA; Huang, XY; Li, TZ; Shen, C; Sun, JJ; Wang, JP; Xue, D, 2021) |
| "Liver fibrosis is pathologically important in the liver cirrhosis progression." | ( Li, L; Liu, Y; Shi, D; Tang, T; Weng, T; Wu, Z; Yan, D; Yao, H; Zhang, H; Zhu, L; Zhu, M, 2021) |
| "Liver fibrosis is a common feature of liver dysfunction during chronic liver diseases and is frequently associated with angiogenesis, a dynamic process that forms new blood vessels from preexisting vasculature." | ( Cai, X; Chen, L; Dong, H; Gu, T; Guo, Y; Li, B; Li, F; Lu, L; Ma, Z; Qu, Y; Shen, B; Zhang, Q, 2021) |
| "Liver fibrosis is one of the leading causes of morbidity and mortality worldwide but lacks any acceptable therapy." | ( Chen, X; Kong, L; Leng, Y; Li, J; Luo, J; Yang, T; Ye, S; Yu, D; Zhang, H; Zhang, M; Zhang, Y; Zhu, X, 2021) |
| "Liver fibrosis is a common consequence of chronic liver diseases involved with the activation of hepatic stellate cells (HSCs) and endoplasmic reticulum (ER) stress." | ( Li, R; Liao, X; Tian, T; Yang, Q; Yu, L; Zhan, W, 2021) |
| "Liver fibrosis is the result of long-term liver injury and has a high incidence worldwide." | ( Bi, X; Cui, B; Guo, M; Li, Q; Wang, S; Yang, Z; Zhang, Q, 2021) |
| "Liver fibrosis is defined as excessive accumulation of extracellular matrix, and results from maladaptive wound healing processes that occur in response to chronic liver injury and inflammation." | ( Ravichandra, A; Schwabe, RF, 2021) |
| "Liver fibrosis is a significant health problem that can cause serious illness and death." | ( Elmorsy, MA; Ghanim, AMH; Metwaly, HA; Younis, NS, 2021) |
| "Liver fibrosis is a common characteristic of chronic liver diseases." | ( Chung, D; Lapenta, K; Nam, JH; Nathanson, MH; Robert, ME; Wang, Q; Yang, X; Zhang, B, 2021) |
| "Chronic liver fibrosis is an inevitable stage for the development of patients with chronic hepatitis B (CHB)." | ( Diao, H; Jiang, J; Li, F; Lin, C; Liu, T; Yao, J; Zhang, X, 2021) |
| "Demand for a cure of liver fibrosis is rising with its increasing morbidity and mortality." | ( Choi, YJ; Hwang, J; Jun, DW; Kang, KW; Kim, H; Kim, HY; Kim, N; Kim, SK; Kim, YM; Lim, SC; Yoon, K, 2021) |
| "Liver fibrosis is a progression of chronic liver disease characterized by excess deposition of fibrillary collagen." | ( Chang, ML; Chen, HL; Hou, YC; Kung, HN; Lin, YT; Liu, JJ; Pan, MH; Tsai, PJ; Yu, CH, 2021) |
| "Liver fibrosis is a chronic liver disease with excessive production of extracellular matrix proteins, leading to cirrhosis, hepatocellular carcinoma, and death." | ( Abbas, A; Ahmad, S; Ahmed, A; Ali, U; Chen, G; Hussain, A; Khan, H; Liu, D; Qiu, Z; Raza, F; Shafiq, M; Ullah, A; Usman, M; Zheng, M; Zhou, Z, 2021) |
| "Liver fibrosis is a progressive disease accompanied by the deposition of extracellular matrix (ECM)." | ( Cheng, F; Li, X; Ni, M; Qiu, J; Rao, J; Shi, C; Wang, H; Wang, Y; Wang, Z; Wei, S; Yang, W, 2021) |
| "Liver fibrosis is a pathological process characterized by an exacerbated cicatricial response in the hepatic tissue, which compromises liver function." | ( Antunes, GL; Bastos, MS; Carlessi, LP; Cassel, E; de Souza Basso, B; Donadio, MVF; Gracia-Sancho, J; Haute, GV; Levorse, VG; Luft, C; Ortega-Ribera, M; Rodrigues de Oliveira, J; Santarém, ER, 2021) |
| "The staging of liver fibrosis is clinically important, and a less invasive method is preferred." | ( Bito, Y; Fujiwara, T; Harada, T; Harashima, K; Kudo, K; Nishida, M; Ogawa, K; Sato, R; Shirai, T; Suzuki, J; Yoshikawa, M, 2022) |
| "Liver fibrosis is the strongest prognostic factor for clinical outcomes, liver-related mortality and liver transplantation." | ( French, SW; Hui, ST; Lusis, AJ; Magyar, CE; Parhami, F; Stappenbeck, F; Wang, F, 2021) |
| "Liver fibrosis is characterized by the accumulation of extracellular matrix (ECM) resulting in the formation of fibrous scars." | ( Gaiser, C; Krähenbühl, S; Messner, CJ; Özkul, D; Schmidt, S; Suter-Dick, L; Terracciano, L, 2021) |
| "Liver fibrosis is one of the most common pathological consequences of chronic liver diseases (CLD)." | ( He, HW; Hu, SJ; Lu, ZN; Shan, Q; Wang, JX; Yu, DK; Zhang, GN; Zhao, Y; Zhu, M, 2021) |
| "Liver fibrosis is the consequence of chronic liver injury and is a major challenge to global health." | ( Ding, Y; Huang, C; Li, J; Ma, T; Xu, S; Zhang, Y; Zhao, H; Zhu, H, 2021) |
| "To determine if liver cirrhosis is associated with reduced efficacy of insulin-glucose treatment in moderate to severe hyperkalaemia." | ( Abasszade, JH; Crnobrnja, L; Jiang, C; Lim, AKH; Metlapalli, M; Pham, JH; Wang, RSH, 2021) |
| "Liver fibrosis is the static and main (70%-80%) component of portal hypertension (PH)." | ( Bauer, D; Brusilovskaya, K; Hartl, L; Herac, M; Hofer, BS; Königshofer, P; Lampichler, K; Mandorfer, M; Oberhuber, G; Petrenko, O; Podesser, BK; Reiberger, T; Robl, B; Schwabl, P; Sibila, M; Simbrunner, B; Stift, J; Timelthaler, G; Trauner, M; Wöran, K, 2022) |
| "Liver fibrosis is a major global health concern." | ( Pan, JC; Tu, LL; Yin, LN; Zhang, Y; Zhang, YW; Zheng, GL, 2021) |
| "Liver fibrosis is a complex process characterized by the excessive accumulation of extracellular matrix (ECM) and an alteration in liver architecture, as a result of most types of chronic liver diseases such as cirrhosis, hepatocellular carcinoma (HCC) and liver failure." | ( González, DR; Herrera Vielma, F; Rodríguez, MJ; Sabaj, M; Tolosa, G; Zúñiga, MJ; Zúñiga-Hernández, J, 2021) |
| "At present, liver fibrosis is a major challenge of global health." | ( Chen, Z; Cheng, X; Li, D; Li, Y; Wang, S; Xiong, Y; Xu, Y; Zheng, WV; Zhou, T, 2022) |
| "Liver fibrosis is a dysregulated wound-healing process in response to diverse liver injuries, and an effective drug therapy is not yet available." | ( Chen, G; Chen, J; Hu, Y; Liu, P; Liu, W; Liu, Y; Mu, Y; Xu, Y; Yang, H; Zhang, C; Zhang, D; Zhang, H; Zhang, L, 2021) |
| "Liver fibrosis is an inevitable stage in the development of chronic liver disease to cirrhosis." | ( Gong, H; Gong, J; Liu, Y; Tao, X; Zhang, H, 2022) |
| "Liver fibrosis is a major consequence of chronic liver disease, where excess extracellular matrix is deposited, due caused by the activation of hepatic stellate cells (HSCs)." | ( Ishikawa, T; Kaneko, YK; Kimura, T; Motohashi, N; Ohbayashi, S; Ooka, A; Saito, SY; Yamaguchi, M; Yamashita, H, 2022) |
| "Liver fibrosis is a key transformation stage and also a reversible pathological process in various types of chronic liver diseases." | ( Fan, Q; Fu, L; Geng, J; Li, C; Liang, B; Liu, J; Luo, J; Tan, X; Wu, Y; Zhan, M; Zhang, L; Zhang, Z; Zhu, T; Zou, X, 2022) |
| "Liver fibrosis is a chronic wound-healing response to liver injury of various origins and represents a major health problem." | ( Abdelhameed, MF; Afifi, NA; El-Eraky, W; El-Fadaly, AA; El-Rahman, SSA; Ramadan, A; Salama, A, 2022) |
| "Concomitant liver cirrhosis is a crucial risk factor for major surgeries." | ( Bockhorn, M; Grass, JK; Izbicki, JR; Kemper, M; Küsters, N; Melling, N; Perez, D; Piecha, F; Reeh, M; Tintrup, J, 2022) |
| "Liver fibrosis is initial stage of any chronic liver disease and its end stage is develops into cirrhosis." | ( Afridi, SG; Ayaz, M; Iqbal, M; Khan, A; Khan, B; Khan, HA; Quraish, S; Rafiq, H; Shams, S; Sher, A; Siraj, F, 2022) |
| "Liver fibrosis is a dynamic and highly integrated pathological process resulting from repeated liver injury healing accompanied by inflammation and extracellular matrix deposition." | ( Dai, R; Feng, W; Li, B; Li, J, 2022) |
| "Liver fibrosis is a common chronic hepatic disease." | ( Alharbi, FM; Alhusaini, AM; Alshanwani, AR; Arafah, MM; Badr, AM; Faddah, LM; Fayed, A; Hagar, H; Shaheen, S; Sharma, AK, 2022) |
| "Liver fibrosis is a chronic disease resulting from repetitive or prolonged liver injury with limited treatment options." | ( Nagasaki, Y; Nishikawa, Y; Tran, HT; Vong, LB, 2022) |
| "Liver fibrosis is a global health problem caused by a number of diseases related to liver damage." | ( Chai, YN; Chen, LY; Duan, F; Duan, FY; Han, XY; Qiu, JL; Zhang, HJ, 2022) |
| "Liver fibrosis is a major disease that threatens people's health around the world." | ( Chen, Y; Gao, L; Huang, S; Kuang, S; Lai, Y; Lv, Z; Mo, C; Wang, Y; Xie, S; Zeng, T; Zeng, Z; Zhou, C, 2022) |
| "Liver fibrosis is a major cause of morbidity and mortality in patients with chronic liver inflammation such as that caused by non-alcoholic steatohepatitis." | ( Cho, K; Jung, HJ; Kim, SY; Oh, SH; Seong, JK, 2022) |
| "Liver fibrosis is caused by continuous wound healing responses to various harmful stimuli, including viral infection, drugs, alcohol, and autoimmune liver disease." | ( Chen, K; Chen, Y; Li, D; Li, W; Liu, H; Liu, L; Liu, Y; Lu, J; Ma, D; You, J; Zhang, L, 2022) |
| "Liver fibrosis is a reversible pathological process, and its prevention and treatment hold great significance for patients with chronic liver disease." | ( Jiang, R; Wang, J; Zhao, T; Zheng, Y, 2022) |
| "Liver fibrosis is a prevalent liver disease that requires rapid and effective treatment prior to its progression to cirrhosis and liver damage." | ( Albogami, SM; Alotaibi, SS; Batiha, GE; Elewa, YHA; Makled, S; Mostafa-Hedeab, G; Yassin, F; Zein, N, 2022) |
| "Liver fibrosis is an important process in chronic liver disease and is strongly related to poor prognosis." | ( Bao, YY; Chen, MH; Ge, MX; He, HW; Li, Y; Li, YM; Lu, ZN; Niu, WX; Zhang, N, 2022) |
| "Liver fibrosis is an independent contributor of chronic liver diseases, and regressing liver fibrosis is considered a potential therapeutic target for chronic liver diseases." | ( Chen, XF; Ji, S, 2022) |
| "Liver fibrosis is a progressive liver injury response." | ( Cao, Z; Chu, Y; Liu, J; Liu, Y; Pan, Y; Qiu, Y; Shi, J; Song, X; Wu, D; Yu, Y; Yuan, X, 2022) |
| "Liver fibrosis is a wound-healing response to chronic injury, featuring with excess accumulation of extracellular matrix secreted by the activated hepatic stellate cells (HSC)." | ( Li, D; Li, J; Ma, X; Nie, HZ; Wang, X; Wang, YH; Wu, Z; Yang, XM; Zhou, Y; Zhu, L, 2022) |
| "Liver fibrosis is a common cause of chronic liver disease." | ( Chen, K; Gao, Q; Guo, W; Han, Y; Li, R; Wang, S, 2022) |
| "Liver fibrosis is characterized by the abnormal deposition of the extracellular matrix with a severe inflammatory response and/or metabolic disorder." | ( Guan, S; He, XL; Huang, XZ; Li, J; Li, S; Li, Y; Zhang, L; Zhou, LP, 2022) |
| "Liver fibrosis is a serious cause of morbidity and mortality worldwide characterized by accumulation of extracellular matrix produced by hepatic stellate cells (HSCs)." | ( Chen, R; Chen, X; Chen, Y; Cong, W; Dong, Y; Fan, J; Gong, W; Hu, Z; Jin, L; Li, S; Tong, G; Yu, Y; Zhou, B; Zhu, J; Zhu, K; Zhu, S, 2023) |
| "Liver fibrosis is one main histological characteristic of nonalcoholic steatohepatitis (NASH), a disease paralleling a worldwide surge in metabolic syndromes with no approved therapies." | ( Ding, BS; Mo, C; Xiao, C; Zhang, J; Zhou, D, 2022) |
| "Liver fibrosis is a pathological process of multiple chronic liver diseases progressing to cirrhosis for which there are currently no effective treatment options." | ( Bi, J; Cao, Y; Li, J; Li, Y; Liang, Q; Liu, J; Liu, Y; Yang, J; Zhou, L, 2022) |
| "Liver fibrosis is mainly characterized by the formation of fibrous scars." | ( Liu, JY; Liu, XY; Piao, JS; Piao, MG; Wu, ZC, 2022) |
| "Liver fibrosis is a common scarring response and may ultimately lead to liver cancer, unfortunately, there is currently no effective antifibrotic drug approved for human use." | ( Dong, R; Kong, L; Leng, Y; Liu, J; Luo, J; Wu, E; Xu, W; Yang, T; Ye, S; Zhang, H; Zheng, Y; Zhong, J; Zhu, X, 2022) |
| "Liver fibrosis is a disorder in which inflammatory reactions play an important role, and central to the progression and pathogenesis of this disease are the immune-specific cells known as macrophages." | ( Baghaei, K; Farivar, S; Hatami, B; Malmir, A; Mazhari, S; Rezaei, R; Tokhanbigli, S, 2023) |
| "Schistosoma mansoni liver fibrosis is a complicated multicellular process involving numerous cytokines, chemokines, and growth factors." | ( Abd Allah, MH; Abo-Sheishaa, GA; Bayoumy, AS; Shalash, IR; Zaalouk, TK, 2022) |
| "Liver fibrosis is a wound-healing response caused by the abnormal accumulation of extracellular matrix, which is produced by activated hepatic stellate cells (HSCs)." | ( Chen, H; Hou, L; Wei, M; Xin, X; Yan, X; Zhang, J, 2022) |
| "Hepatic cirrhosis is a major health problem across the world, causing high morbidity and mortality." | ( Aleknavičiūtė-Valienė, G; Banys, V, 2022) |
| "Background: Liver cirrhosis is a life-threatening seqsuel of many chronic liver disorders of varying etiologies." | ( Atkin, SL; Banach, M; Jamialahmadi, T; Mahmoudi, A; Sahebkar, A, 2022) |
| "Liver fibrosis is a global life-threatening disorder with no approved treatment." | ( Ashour, AA; El-Kamel, AH; Heikal, LA; Mehanna, RA; Mourad, G, 2022) |
| "Liver fibrosis is the result of a chronic pathological condition caused by the activation of hepatic stellate cells (HSCs), which induces the excessive deposition of extracellular matrix." | ( Carpi, S; Carrara, M; Cazzagon, N; Colognesi, M; De Martin, S; Digiacomo, M; Gabbia, D; Guido, M; Macchia, M; Nieri, P; Polini, B; Russo, FP; Sarcognato, S; Sayaf, K; Zanotto, I, 2023) |
| "Liver fibrosis is the result of a chronic pathological condition caused by the activation of hepatic stellate cells (HSCs), which induces the excessive deposition of extracellular matrix." | ( Carpi, S; Carrara, M; Cazzagon, N; Colognesi, M; De Martin, S; Digiacomo, M; Gabbia, D; Guido, M; Macchia, M; Nieri, P; Polini, B; Russo, FP; Sarcognato, S; Sayaf, K; Zanotto, I, 2023) |
| "Liver fibrosis is the result of a chronic pathological condition caused by the activation of hepatic stellate cells (HSCs), which induces the excessive deposition of extracellular matrix." | ( Carpi, S; Carrara, M; Cazzagon, N; Colognesi, M; De Martin, S; Digiacomo, M; Gabbia, D; Guido, M; Macchia, M; Nieri, P; Polini, B; Russo, FP; Sarcognato, S; Sayaf, K; Zanotto, I, 2023) |
| "Liver fibrosis is one of the major liver complications which eventually progresses to liver cirrhosis and liver failure." | ( Godugu, C; Khurana, A; Saifi, MA, 2023) |
| "Liver fibrosis is one of the major liver complications which eventually progresses to liver cirrhosis and liver failure." | ( Godugu, C; Khurana, A; Saifi, MA, 2023) |
| "Liver fibrosis is one of the major liver complications which eventually progresses to liver cirrhosis and liver failure." | ( Godugu, C; Khurana, A; Saifi, MA, 2023) |
| "Liver fibrosis is an excessive wound-healing response governed by activated hepatic stellate cells (HSCs)." | ( Fan, C; Gan, C; Liu, H; Su, X; Tan, Z; Xie, Y; Xue, T; Ye, T; Yue, L; Zhu, G, 2023) |
| "Liver fibrosis is an excessive wound-healing response governed by activated hepatic stellate cells (HSCs)." | ( Fan, C; Gan, C; Liu, H; Su, X; Tan, Z; Xie, Y; Xue, T; Ye, T; Yue, L; Zhu, G, 2023) |
| "The hallmark of liver fibrosis is excessive scarring of liver tissue, triggered by hepatocellular injury and subsequent activation of hepatic stellate cells (HSCs)." | ( Gaiser, C; Hämmerli, C; Messner, CJ; Schmidt, S; Suter-Dick, L, 2022) |
| "The hallmark of liver fibrosis is excessive scarring of liver tissue, triggered by hepatocellular injury and subsequent activation of hepatic stellate cells (HSCs)." | ( Gaiser, C; Hämmerli, C; Messner, CJ; Schmidt, S; Suter-Dick, L, 2022) |
| "The severity of liver fibrosis is an important predictor of death in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM)." | ( He, W; Huang, C; Huang, P; Huang, Y; Li, X; Lin, M; Shi, X; Su, W; Wang, L; Wang, S; Zhang, X; Zhao, Y, 2022) |
| "The severity of liver fibrosis is an important predictor of death in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM)." | ( He, W; Huang, C; Huang, P; Huang, Y; Li, X; Lin, M; Shi, X; Su, W; Wang, L; Wang, S; Zhang, X; Zhao, Y, 2022) |
| "Liver fibrosis is a wound-healing response to acute or chronic cellular damage of liver tissue." | ( Lan, H; Li, H; Xing, B, 2022) |
| "Liver fibrosis is a wound-healing response to acute or chronic cellular damage of liver tissue." | ( Lan, H; Li, H; Xing, B, 2022) |
| "Liver fibrosis is a potentially harmful chronic liver disease caused by various etiologies." | ( Cao, W; Feng, YD; Li, WY; Li, XQ; Liu, CX; Liu, SY; Meng, JR; Sun, Y; Tian, W; Wang, SJ; Ye, W; Zhang, M, 2023) |
| "Liver fibrosis is a potentially harmful chronic liver disease caused by various etiologies." | ( Cao, W; Feng, YD; Li, WY; Li, XQ; Liu, CX; Liu, SY; Meng, JR; Sun, Y; Tian, W; Wang, SJ; Ye, W; Zhang, M, 2023) |
| "Liver fibrosis is caused by the excessive deposition of extracellular matrix and concomitant collagen accumulation in livers and can lead to the development of liver cirrhosis and even liver cancer." | ( Du, X; Li, H; Li, N; Li, Z; Mao, L; Niu, Y; Wang, L; Xu, W; Zhang, P, 2023) |
| "Liver fibrosis is a progressive pathological process induced by various stimuli and may progress to liver cirrhosis and cancer." | ( Fu, K; Gong, L; Li, Y; Ma, C; Peng, C; Wang, C; Zhang, S; Zhang, Y; Zhou, H, 2023) |
| "Liver fibrosis is a pathophysiological process, and its persistence can seriously affect the quality of life and well-being of the patients." | ( Dong, J; Du, C; Feng, R; Feng, S; Huang, C; Li, J; Lv, X; Ma, T; Wang, Q; Xu, C; Zhang, L, 2023) |
| "Liver fibrosis is one of the most common liver diseases with substantial morbidity and mortality." | ( Cai, J; Li, Q; Liu, X; Liu, Z; Ren, H; Wang, L; Xia, S; Yue, J; Zhang, H; Zhou, Q; Zhou, T; Zhou, X, 2023) |
| "Liver fibrosis is a disease with significant morbidity and mortality." | ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023) |
| "Liver fibrosis is a chronic liver disease with the presence of progressive wound healing response caused by liver injury." | ( Chen, J; Dai, Z; Feng, T; Huang, X; Lai, C; Liang, Y; Shang, J; Shi, Y; Su, Y; Sun, L; Yan, S; Yang, Q; Yao, Y; Zhang, Z; Zhong, D; Zou, H, 2023) |
| "Liver fibrosis is the underlying causeof hepatitis C virus (HCV)-related disease progression to endpoints such as cirrhosis, liver failure, and hepatocellular carcinoma." | ( Abdel-Rahman, YO; Abdel-Razik, W; Dabbous, HM; Elakel, W; Elmakhzangy, H; Elshafaey, A; Esmat, G; Ismail, SA; Omar, H; Saeed, R; Salama, R; Waked, I; Ziada, DH, 2023) |
| "Development of liver fibrosis is paralleled by contraction of hepatic stellate cells (HSCs), the main profibrotic hepatic cells." | ( Alfonso-Prieto, M; Brol, M; Dietrich, P; Gröschl, S; Hellerbrand, C; Hieber, C; Keller, UAD; Klein, S; Kraus, N; Magdaleno, F; Meier, C; Mira, F; Moore, A; Ortiz, C; Poglitsch, M; Reul, WH; Schierwagen, R; Tetzner, A; Torres, S; Trebicka, J; Tyc, O; Uschner, FE; Walther, T; Welsch, C; Zeuzem, S, 2023) |
| "Liver fibrosis is a worldwide public health problem due to its life-threatening complications, including portal hypertension, liver failure, cirrhosis, and hepatocellular carcinoma (HCC)." | ( Erdem Koc, G; Gokcimen, A; Sahin, F, 2023) |
| "Methotrexate-induced liver fibrosis is not a well-defined pathology, and many of the reported cases can instead be classified as nonalcoholic fatty liver disease by current diagnostic criteria, which is particularly common in the psoriasis cohort." | ( Aspinall, RJ; Hamilton, J; Livesey, A; Raahimi, MM; Shipman, AR, 2023) |
| "Liver fibrosis is a leading indicator for increased mortality and long-term comorbidity in NASH." | ( Chen, S; Cheng, J; Dong, L; Fu, R; Han, P; Li, R; Li, S; Liu, Z; Pei, H; Shen, X; Song, G; Song, Y; Wang, H; Wei, J; Wu, J; Yao, Q; Zhang, G; Zhang, S; Zhao, Y; Zhu, C; Zhu, J, 2023) |
| "Liver fibrosis is the end stage of almost all chronic liver diseases, such as non-alcoholic fatty liver disease, and at the moment, there is no effective anti-fibrotic therapy available." | ( Buechler, C; Mester, P; Treeck, O; Weber, F, 2023) |
| "Alcohol-related liver fibrosis is characterized by selective and progressive lipid depletion in liver and blood, particularly sphingomyelins, which also associates with progression to liver-related events." | ( Anastasiadou, E; Andersen, P; Bork, P; de Zawadzki, A; Detlefsen, S; Filippa, V; Georgiou, S; Hansen, T; Israelsen, M; Juel, HB; Kim, M; Kjaergaard, M; Krag, A; Kuhn, M; Legido-Quigley, C; Lindvig, KP; Moitinho-Silva, L; Nielsen, T; Nishijima, S; Rasmussen, DN; Rossing, P; Suvitaival, T; Thiele, M; Trebicka, J; Trošt, K, 2023) |
| "Liver fibrosis is associated with gut dysbiosis." | ( Geng, Y; Guan, Q; Shi, JS; Xu, ZH; Yang, T, 2023) |
| "Liver fibrosis is a pathological response driven by the activation of hepatic stellate cell (HSC)." | ( Cai, X; Dai, W; Dong, H; Guo, Y; Lu, L; Shen, Z; Wang, J, 2023) |
| "Liver fibrosis is a chronic progressive disease, its resolution still unclear, and the current study explored the role of melatonin in modulation of interleukin-6 (IL-6), interleukin-4 (IL-4), transforming growth factor beta1 (TGF-β1) and urokinase plasminogen activator receptor-associated protein/Endo180 (uPARAP/Endo180) pathway in thioacetamide (TAA)-induced hepatotoxicity." | ( Al-Khater, KM; Alasmari, WA; Alghamdi, MA; Almohawes, ZN; El Nashar, EM; El-Kott, AF; Eladl, AE; Elalfy, MM; Elhadidy, MG; Elmasry, AI; Hamed, EM; Rabei, MR; Shati, AA, 2022) |
| "Liver fibrosis is a reversible wound-healing response that can lead to end-stage liver diseases without effective treatment, in which HBV infection is a major cause." | ( Cai, C; Chu, T; Fang, F; Feng, S; Feng, Y; Gao, B; He, M; Liu, Y; Lu, L; Shi, R; Wang, Z; Zhang, X, 2023) |
| "Liver fibrosis is a key global health care burden." | ( Bao, YY; Ge, MX; He, HW; Lu, ZN; Niu, WX, 2023) |
| "Liver fibrosis is a crucial progress to deteriorate liver disease." | ( Cao, J; Cheng, G; Khan, A; Liu, Y; Sun, P; Wang, Z; Zhao, T; Zhou, W, 2023) |
| "Liver fibrosis is a grievous global challenge, where hepatic stellate cells (HSCs) activation is a paramount step." | ( Mou, Q; Ren, T; Wang, Y; Wang, Z; Zhang, Y; Zhu, L, 2023) |
| "Liver fibrosis is a significant cause of morbidity and mortality without approved treatment." | ( Baghaei, K; Hashemi, N; Hatami, B; Mazhari, S; Mousazadeh, H; Reza Zali, M; Rezaei, R; Siapoush, S, 2023) |
| "The evaluation of liver fibrosis is essential in the management of patients with autoimmune hepatitis (AIH)." | ( Chen, Y; Huang, R; Li, J; Li, Y; Liu, J; Liu, Y; Qiu, Y; Tong, X; Wang, H; Wang, J; Wu, C; Xiong, Y; Yan, X; Yang, Y; Yin, S; Zhang, Q; Zhang, Z; Zhu, C; Zhu, L, 2023) |
| "On a global scale, liver cirrhosis is attributable to ~1 million deaths per year." | ( Egger, M; Fickert, P; Finkelman, M; Grønbaek, H; Hoenigl, M; Horvath, A; Krause, R; Kriegl, L; Møller, HJ; Prattes, J; Prüller, F; Stadlbauer, V, 2023) |
| "Excessive liver fibrosis is frequently observed in chronic liver diseases and associated with decline of liver functions." | ( Guo, Y; Li, Z; Wu, X; Zhao, Z; Zhu, Y, 2023) |
| "Liver fibrosis is the most common feature of liver disease, and activated hepatic stellate cells (HSCs) are the main contributors to liver fibrosis." | ( Choi, YH; Han, J; Jeong, H; Jung, Y; Kim, J; Lee, C; Wang, S, 2023) |
| "Liver fibrosis is characterized by the excessive deposition and accumulation of extracellular matrix components, mainly collagens, and occurs in response to a broad spectrum of triggers with different etiologies." | ( Alavifard, H; Baghaei, K; Ghavami, S; Hatami, B; Lorzadeh, S; Rezaei, R; Siapoush, S; Vosough, M; Zali, MR; Łos, MJ, 2023) |
| "Liver fibrosis is caused by chronic hepatic injury and may lead to cirrhosis, and even hepatocellular carcinoma." | ( Ding, X; Shen, W; Wang, Q; Ye, B; Yin, M; Yu, M; Yue, M; Zhang, C; Zhao, Z, 2023) |
| "Liver fibrosis is featured by activation of hepatic stellate cells (HSCs) and excessive accumulation of extracellular matrix (ECM)." | ( Chen, W; He, J; Huang, Y; Jia, Q; Li, Y; Liu, Q; Mo, L; Tang, Q; Xia, Y; Xiong, Y; Xu, Y; Zhang, J; Zhang, T, 2023) |
| "Liver fibrosis is a reversible pathological process and a wound healing response to liver injury." | ( Chen, C; Chen, P; Gu, Y; Li, S; Liu, F; Wang, L; Wang, R; Wang, S; Yuan, Y, 2023) |
| "Liver fibrosis is a worldwide challenge of health issue." | ( Guo, FY; Jin, CH; Lian, LH; Lin, YC; Nan, JX; Wu, YL; Yang, HX, 2023) |
| "Liver fibrosis is one of the histopathological characters during Echinococcus multilocularis infection." | ( Cao, S; Guo, X; Luo, X; Pu, L; Sun, X; Wang, D; Wang, S; Wu, Y; Zhang, J; Zhang, X; Zheng, Y, 2023) |
| "Liver fibrosis is a global health problem, and studying its development provides important information to address its treatment." | ( de Sánchez, VC; de Vaca, RP; Domínguez-López, M; Guerrero-Celis, N; Rodríguez-Aguilera, JR; Velasco-Loyden, G, 2023) |
| "Currently, liver fibrosis is growing worldwide; unfortunately, there is no definite cure for this disease." | ( Beheshti Nasab, H; Cheraghzadeh, M; Matour, E; Rashidi, M; Shakerian, E, 2023) |
| "Liver fibrosis is the pathological process of chronic liver diseases induced by hepatic stellate cells." | ( Hu, M; Li, X; Liu, Y; Wang, L; Xiao, Y, 2023) |
| "Liver fibrosis is a progressive and debilitating condition characterized by the excessive deposition of extracellular matrix proteins." | ( Cha, JY; Hwang, S; Lee, HJ; Park, S; Yaseen, U, 2023) |
| "Liver fibrosis is a chronic inflammatory process characterized by the accumulation of extracellular matrix (ECM), which contributes to cirrhosis and hepatocellular carcinoma." | ( Bao, B; Chen, L; Chen, X; Li, C; Sun, Y; Zhou, Y, 2023) |
| "Liver fibrosis is a wound-healing reaction that eventually leads to cirrhosis." | ( Cai, X; Dong, H; Guo, Y; Lu, J; Lu, L; Luo, X; Luo, Y; Qu, Y; Shen, B; Shen, Z; Sun, Z; Wang, J; Xu, X; Ye, Y; Zhang, Q; Zhou, C, 2023) |
| "Liver fibrosis is a major global health issue, and immune dysregulation is a main contributor." | ( Feng, J; Jiang, S; Jiang, Y; Kong, J; Li, J; Li, X; Li, Y; Lian, H; Lu, Z; Zhang, F, 2023) |
| "Liver fibrosis is a common and reversible feature of liver damage associated with many chronic liver diseases, and its onset is influenced by sex." | ( Alberti, D; De Martin, S; Fantin, A; Gabbia, D; Pasqual, G; Russo, FP; Sayaf, K; Zanotto, I; Zaramella, A, 2023) |
| Excerpt | Reference |
|---|
| "The results indicate that in some cases, liver fibrosis could be modified by treatment with antifibrotic drugs." | ( Kershenobich, D; Mata, JM; Pérez-Tamayo, R; Rojkind, M; Suárez, GI; Uribe, M, 1979) |
| "Chemical and histological indices of liver fibrosis were measured after eight, 18 and 28 weeks in mice infected with Schistosoma mansoni and treated at eight weeks with oxamniquine, in mice infected with S." | ( Girgis, NI; Ishak, EA; Khayyal, MT; Mansour, MM; Morcos, SH; Saleh, S, 1992) |
| "Because of severe liver cirrhosis, the patient was treated with interferon (IFN) alone (natural IFN 6 x 10(6) IR/day i." | ( Ashihara, E; Nakamura, M; Nishio, A; Oku, N; Tuji, K, 1992) |
| "The effect of D-penicillamine (Pe) on liver fibrosis-cirrhosis induced by chronic CCl4 and phenobarbital (Pb) administration in Fischer 344 male rats was studied." | ( Divald, A; Gergely, P; Jeney, A; Lapis, K; Major, J; Schaff, Z; Simon, K; Szende, B; Timár, F, 1991) |
| "In patients suffering from liver cirrhosis with secondary gastroduodenal ulcers or multiple erosions, the 5-week treatment either with almagel and platyphylline or gastrozepine provided approximately similar results and promoted ulcer and erosion healing in half the cases." | ( Bessonova, GA; Geller, LI; Griaznova, MV, 1991) |
| "He developed nonA-nonB-induced liver cirrhosis and had been treated with spironolactone for the last 6 years." | ( Bou-Abboud, CF; Nemec, F; Toffel, F, 1990) |
| "According to our examinations in case of liver fibrosis cirrhosis induced by CCL4-PB treatment in rats the Pe treatment proved to be unsuccessful." | ( Divald, A; Gergely, P; Gonzales Cabello, R; Jeney, A; Lapis, K; Major, J; Schaff, Z; Simon, K; Szende, B; Timár, F, 1990) |
| "At the instance of two patients with liver cirrhosis, whose simultaneous hyperthyroidism was treated thyreostatically, the therapeutic problems are represented." | ( Klaua, M; Mertens, E; Nilius, R; Rink, C; Schneider, G, 1985) |
| "The prognoses of the decompensated liver cirrhosis patients treated with malotilate were significantly better than those who did not receive malotilate." | ( Matsuda, Y; Sato, H; Takada, A; Takase, S; Yasuhara, M, 1988) |
| "In experimentally induced liver cirrhosis, however, an excessive amount of glucose administration in the early postoperative period induced the reduction of hepatic energy charge and ATP content." | ( Matsuno, S; Nakagawa, K; Ouchi, K; Sakai, K; Sato, R; Sato, T, 1988) |
| "In patients with decompensated liver cirrhosis, the reduction in the TBA and CDCA levels after the peaks was slow, and GCDCA and TCDCA levels continued to increase until 180 min after the administration of CDCA." | ( Adachi, Y; Itoh, T; Kurumi, Y; Nanno, T; Sawada, Y; Yamamoto, T; Yamazaki, K, 1988) |
| "Patients with liver cirrhosis were classified into a normal glucose tolerance group (NGT), an impaired glucose tolerance group (IGT), and a diabetes mellitus group (DM) on the basis of the glucose tolerance curves obtained after the oral administration of glucose." | ( Kawakami, K, 1988) |
| "To investigate the influence of liver cirrhosis on the capacity of methylation, the urinary excretion of the methylated forms of arsenic was measured by atomic absorption spectrometry after the administration of a small dose of inorganic arsenic." | ( Buchet, JP; Dive, C; Geubel, AP; Lauwerys, R; Mairlot, MC, 1988) |
| "Fifty patients with liver cirrhosis (13 Child class B, 37 class C) were treated for variceal hemorrhage during a 3-year period using the transhepatic selective catheterization and injection of absolute ethanol." | ( Becker, GJ; Klatte, EC; O'Connor, KW; Olson, EW; Strickler, SA; Yune, HY, 1985) |
| "For this purpose in 30 patients with liver cirrhosis the time in the NCT was determined and the serum ammonia level (NH3) was measured before the treatment with lactulose and neomycin was started." | ( Haerting, J; Mantel, E; Nilius, R; Rink, C, 1985) |
| "In the patients with liver cirrhosis, plasma endotoxin and ammonia levels decreased rapidly after polymyxin B treatment, and the decreases in endotoxin levels were kept throughout the treatment." | ( Adachi, M; Adachi, Y; Enomoto, M; Hashimoto, T; Inoue, H; Nagamine, Y; Nanno, T; Suwa, M; Yamamoto, T, 1982) |
| "Thirty-seven patients with liver cirrhosis (16 without ascites: group 1; 21 with untreated ascites at the first onset: group 2) were studied during controlled sodium intake (40 mmol/day)." | ( Bernardi, M; De Palma, R; Gasbarrini, G; Santini, C; Trevisani, F, 1983) |
| "During a one week period patients with liver cirrhosis and a control group were treated with a repeated dosage of the new heart glcoside Meproscillarin." | ( Beckmann, H; Burkert, K, 1983) |
| "28 patients with active liver cirrhosis were treated with natural IFN alpha 3-6 MU TIW for 3-17 months (mean, 8 +/- 6)." | ( Iwabuchi, S; Osada, T; Takatori, M; Yoshida, H, 1994) |
| "A 65-year-old woman with liver cirrhosis complicated by hepatocellular carcinoma lost consciousness due to torsades de pointes with prolongation of the QT-interval after 10 days of treatment with terfenadine." | ( Adachi, Y; Kamisako, T; Nakagawa, H; Yamamoto, T, 1995) |
| "Twenty-five liver cirrhosis patients with endoscopically demonstrated gastro-duodenal mucosal damage (microhemorrhages, erosions, ulcers) were treated with misoprostol (prostaglandin E1) 400 mg/die." | ( Abbati, G; Cioni, G; Cristani, A; Rigo, G; Tincani, E; Ventura, E; Ventura, P; Vignoli, A, 1993) |
| "A 65-year-old female patient with liver cirrhosis complicated with hepatocellular carcinoma (HCC) was treated with oral administration of 5'-DFUR (600 mg/day)." | ( Mizuno, M; Ogino, M; Tanaka, Y; Tokuda, H; Yamauchi, M, 1996) |
| "A 77-year-old male with liver cirrhosis was admitted to our hospital for further examination and treatment of liver tumor." | ( Matsumoto, K; Onodera, H; Otawa, K; Sato, T; Ukai, K, 1996) |
| "CC14-induced liver fibrosis regressed more rapidly in polyenylphosphatidylcholine-treated animals than controls, both histologically and by measurement of collagen (p < 0." | ( Lieber, CS; Ma, X; Zhao, J, 1996) |
| "In conclusion, patients with liver cirrhosis of varying etiology and varying medical treatment did not show alterations of riboflavin turnover." | ( Galloway, JR; McCormick, DB; Zempleni, J, 1996) |
| "Twelve patients with liver cirrhosis complaining of painful muscle cramps were treated with Niuche-Shen-Qi-Wan (TJ-107)." | ( Motoo, Y; Okai, T; Sawabu, N; Taga, H; Watanabe, H; Yamaguchi, Y, 1997) |
| "Non-invasive markers of liver fibrosis have great potential for both the diagnosis and therapy of liver disease and cirrhosis." | ( Afdhal, NH; Cohen, SB; Keaveny, AP; Maldonado, N; Nunes, DP; O'Brien, M; Stone, PJ, 1997) |
| "Three patients with advanced liver cirrhosis (Child B or C) could no longer be treated after 2 or 3 courses of SMANCS infusion because of hepatic failure." | ( Ebara, M; Fukuda, H; Saisho, H; Sugiura, N; Yoshikawa, M, 1998) |
| "Significant regression of liver fibrosis after therapy was observed in both sustained responders and nonresponders (p<0." | ( Doi, Y; Ito, N; Kawata, S; Kiso, S; Matsuzawa, Y; Oshikawa, O; Shirai, Y; Tamura, S; Tsushima, H; Yamada, A, 1999) |
| "Fifty patients with liver cirrhosis were divided into two groups at random, after informed consents were obtained, to receive prophylactic therapy for bleeding of oesophageal varices." | ( Fujimoto, K; Gotoh, Y; Ishibashi, S; Iwakiri, R; Koyama, T; Matsunaga, C; Noda, T; Ogata, SI; Sakata, H; Sakata, Y; Tsunada, S, 1999) |
| "In 30 patients with liver cirrhosis at high risk for variceal bleeding, duplex Doppler sonographic parameters (maximal portal flow velocity, portal blood flow, and congestion index) were measured before and 4 h after the administration of 40 mg of propranolol." | ( Baraldi, E; Boldrini, E; Cioni, G; Cristani, A; D'Alimonte, P; Pedrazzini, PG; Tincani, E; Turrini, F; Ventura, E; Ventura, P, 1999) |
| "Thirty patients with decompensated liver cirrhosis accepted anti-endotoxin therapy with oral Amoxycillin and Smedta for 2 weeks." | ( Liu, T; Ma, Z; Zhuang, L, 2000) |
| "Several drugs have been tested for the treatment of hepatic cirrhosis induced by various etiologic agents." | ( Armendáriz-Borunda, J; Bueno, MR; Daneri, A, 2000) |
| "In vivo liver fibrosis was induced by dimethylnitrosamine administration and bile duct ligation (BDL) in rats treated or not treated with amiloride." | ( Bendia, E; Benedetti, A; Casini, A; D'Ambrosio, L; Di Sario, A; Feliciangeli, G; Macarri, G; Pigini, P; Ridolfi, F; Svegliati-Baroni, G; Tonnini, C, 2001) |
| "The ideal strategy for the treatment of liver cirrhosis should include prevention of fibrogenesis, stimulation of hepatocyte mitosis, and reorganization of the liver architecture." | ( Fujimoto, J; Okamoto, E; Takeuchi, M; Ueki, T, 2001) |
| "However, liver fibrosis is reversible if antischistosomal drugs are administered before the onset of severe hepatic insufficiency." | ( Dessein, A; Ranque, S, 2001) |
| "Hepatotoxicity, especially liver fibrosis, is the major concern with long-term, 'low-dose' oral methotrexate (MTX) therapy for psoriasis." | ( Hall, PM; Langman, G; Todd, G, 2001) |
| "The de-copper therapy could improve liver cirrhosis and liver function." | ( Hong, M; Wang, G; Yang, R, 2000) |
| "However, we experienced a patient with liver cirrhosis (LC, Child-Pugh class B) in whom severe lactic acidosis developed during RFA conducted for the treatment of a HCC (-4." | ( Akata, T; Kandabashi, T; Kanna, T; Shiokawa, H; Takahashi, S; Yoshino, J, 2002) |
| "To assess the factors associated with liver fibrosis in human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients eligible for anti-HCV therapy, we performed an observational, single-centred, cross-sectional study of 180 HIV/HCV co-infected patients who underwent liver biopsy between May 1998 and November 2001." | ( Ballesteros, A; Clotet, B; Fuster, D; Lasanta, JA; Ojanguren, I; Planas, R; Rey-Joly, C; Sirera, G; Tor, J; Tural, C, 2003) |
| "A 59-year-old man with liver cirrhosis due to hepatitis B virus infection received non-myeloablative stem-cell transplantation (NST) for the treatment of adult T-cell lymphoma." | ( Arase, Y; Hamaki, T; Hayashi, M; Igarashi, M; Ishibashi, T; Kami, M; Kusumi, E; Miyakoshi, S; Morinaga, S; Mutou, Y; Shimamura, K; Takaue, Y, 2003) |
| "These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis." | ( Lai, CL; Poynard, T; Ratziu, V; Yuen, MF, 2003) |
| "Tumor type, tumor size and grade of liver cirrhosis have an independent impact on prognosis of patients with HCC treated by TACE." | ( Benda, N; Claussen, CD; Duda, SH; Huppert, PE; Kloska, SP; Lauchart, W; Pereira, P; Torkler, C; Weinlich, M, 2004) |
| "Following confirmation of CCl(4)-induced liver fibrosis, GbE or saline was administrated to the rats for 4 weeks." | ( Luo, YJ; Shi, ZH; Wang, L; Yu, JP, 2004) |
| "Compared with saline-treated group, liver fibrosis rats treated with GbE had decreased serum total bilirubin (P<0." | ( Luo, YJ; Shi, ZH; Wang, L; Yu, JP, 2004) |
| "Any complication related with liver cirrhosis was not observed during treatment period despite spontaneous ascitic infection in one and hepatic coma in two were occurred before therapy." | ( Ahmet, D; Atilla, O; Cetin, K; Fatih, B; Güngör, B; Kadir, D; Mürüvvet, B; Sabahattin, K; Selim, B; Yilmaz, C; Zeynel, M; Ziyaettin, D, 2003) |
| "Forty women diagnosed as having viral liver cirrhosis were admitted to a university hospital between 1996 and 1998 and were randomly assigned to the treatment or control group." | ( Habu, D; Kubo, S; Nishiguchi, S; Shiomi, S; Takeda, T; Tamori, A; Tanaka, T, 2004) |
| "At present, no effective treatment of liver fibrosis is available for clinical use." | ( Aydin, S; Aytekin, H; Canbakan, B; Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tahan, V; Uzun, H; Yildirim, B, 2004) |
| "Fifteen patients with liver cirrhosis, portal hypertension and chronic hepatic encephalopathy were treated, beside the standard therapy, also with one capsule of probiotic "Enterococcus faecium M-74 + Selenium" per day in three four-week periods, separated by two fortnight pauses." | ( Boca, M; Buzgová, D; Ebringer, L; Kolibás, E; Kratochvíl'ová, H; Mikulecký, M; Vyskocil, M, 2004) |
| "The strategy for treating liver fibrosis in chronic hepatitis patients includes dispelling the etiological factors, inhibiting the inflammatory reaction, decreasing the sedimentation of extracellular matrix, accelerating the degradation of extracellular matrix, improving the microcirculatory and metabolic disturbance, and ameliorating the complicating diseases, etc." | ( Liu, P, 2004) |
| "The data show that TAA caused liver fibrosis in rat after 30 d of treatment." | ( Fan, S; Weng, CF, 2005) |
| "The increased liver fibrosis observed in renal transplant patients receiving ribavirin monotherapy could be related to ribavirin-induced anemia." | ( Boulestin, A; Chatelut, E; Durand, D; Esposito, L; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J; Stébenet, M, 2005) |
| "Treatment of liver fibrosis in chronic hepatitis C should affect at least one among elements of fibrosis pathogenesis." | ( Flisiak, R, 2004) |
| "We assessed the changes in liver fibrosis before and after treatment among these patients." | ( Alimohamadi, SM; Hagh-Azali, S; Malekzadeh, R; Mohamadnejad, M; Nasseri-Moghaddam, S; Rakhshani, N; Sedaghat, M; Tavangar, SM, 2005) |
| "We studied 23 patients with liver cirrhosis and PNa < or =131 meq/L to determine the cause of hyponatremia and results of quantitative treatment." | ( Bartoli, E; Castello, L; Pirisi, M; Sainaghi, PP, 2005) |
| "Eighty-five patient with liver cirrhosis complicated by hepatic encephalopathy were divided into therapy group (n=45) and control group (n=40)." | ( Chen, CH; Chen, MF; Gao, XC; Li, RC, 2005) |
| "We present an autopsy case of AD-induced liver cirrhosis in a patient who had been treated with a low dose of AD (200 mg/d) daily for 84 mo." | ( Kotani, K; Maesawa, C; Masuda, T; Oikawa, H; Oikawa, K; Ono, S; Oriso, S; Sato, R; Suzuki, K; Yamada, H; Yashima-Abo, A, 2005) |
| "Interferon alpha may alleviate liver fibrosis and suppress cell apoptosis in patients in S3-S4 stages after a 6- to 9-month continuous treatment." | ( Cao, ZC; Geng, JY; He, ZG; Sun, XY; Wang, ZH; Wang, ZM; Yu, H, 2005) |
| "CCl4 administration induced liver fibrosis, which was inhibited by EGB in a dose-dependent manner." | ( Chen, HL; Chen, SM; Liu, SQ; Luo, HS; Yu, HG; Yu, JP, 2006) |
| "A prospective study to evaluate liver fibrosis with FibroScan and non-invasive biochemical methods in Crohn's disease patients treated with methotrexate." | ( Adhoute, X; Amouretti, M; Bertet, J; Boué-Lahorgue, X; Castéra, L; Couzigou, P; de Lédinghen, V; Foucher, J; Laharie, D; Rullier, A; Zerbib, F, 2006) |
| "The degrees of liver fibrosis in EGb-protected groups were lower than those in CCl(4)-treated groups (6." | ( Fu, H; He, SX; Liu, EQ; Luo, JY; Wang, YL; Wang, YP; Xu, JL; Zhao, G, 2006) |
| "The four liver fibrosis indexes declined significantly in the SMI group after treatment (P < 0." | ( Jin, CX; Sun, HF; Yang, J, 2006) |
| "We report a case of HCC with liver cirrhosis and lung metastases who had been treated successfully by combination chemotherapy of 5-fluorouracil (5-FU) and interferon-alpha (IFN-alpha)." | ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
| "To report a case of early-decompensated liver cirrhosis secondary to discontinuation of penicillamine therapy in a patient with Wilson's disease." | ( Awaisu, A; Aziz, NA; Ghazali, R; Hassan, Y; Ping, CC, 2007) |
| "To assess the influence of liver fibrosis on the outcome of anti-HCV therapy, all patients with genotype 3a hepatitis C who were naive to IFN-based therapies, and received RBV combined with standard IFN or pegylated IFN-(alpha2b (peg-IFN-alpha2b) as standard of care for their disease, were investigated at our centre." | ( Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG; Soffredini, R, 2006) |
| "A 71-year-old man with end-stage liver cirrhosis had been treated for suppurative omarthritis due to methicillin-resistant Staphylococcus aureus (MRSA)." | ( Hamada, H; Kasaoka, S; Maekawa, T; Mizuno, H; Nakahara, T; Oda, Y; Tsuruta, R, 2007) |
| "In recent years, regression of liver fibrosis (occurring spontaneously or during treatment) has been demonstrated in rodent models such as bile duct ligation and CCl(4) administration." | ( Aeed, H; Bruck, R; Halpern, Z; Oren, R; Traister, A; Weiss, S; Zvibel, I, 2007) |
| "However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear." | ( Higami, K; Ikehara, T; Kanayama, M; Matsui, T; Miki, K; Miyaki, D; Momiyama, K; Nagai, H; Sumino, Y; Watanabe, M, 2008) |
| "Forty adult patients with liver cirrhosis (cirrhosis group) and 20 adult individuals with normal liver parenchyma (control group) underwent EOB-MRC using T1-weighted GRE imaging up to 180 min after Gd-EOB-DTPA administration." | ( Kakales, I; Marincek, B; Petrowsky, H; Struwe, A; Tschirch, FT; Weishaupt, D, 2008) |
| "CCl4-induced liver fibrosis in rats was not aggravated by corn oil treatment." | ( Fang, HL; Lin, WC, 2008) |
| "However, data on the progression of liver fibrosis after treatment by celecoxib are not available." | ( Chan, HL; Cheung, KF; Chu, ES; Go, MY; Hui, AY; Sung, JJ; Wu, CW; Yu, J, 2009) |
| "Rats with liver cirrhosis, evoked by chronic administration of thioacetamide (TAA), consumed voluntarily more alcohol than their healthy counterparts." | ( Fogel, WA; Stasiak, A, 2008) |
| "A 55 years old woman with liver cirrhosis treated with venlafaxine for 1 year and propranolol for 1 month was admitted to the intensive care unit because of acute respiratory failure." | ( Dehé, C; Gagnadoux, F; Hureaux, J; Person, C; Priou, P; Racineux, JL; Urban, T, 2008) |
| "Thrombocytosis significantly reduced liver fibrosis and hydroxyproline content of liver tissues compared to mice with CCl(4) administration alone." | ( Aoyagi, Y; Fukunaga, K; Hashimoto, I; Ikeda, O; Matsuo, R; Murata, S; Nakano, Y; Ohkohchi, N; Watanabe, M; Yasue, H, 2009) |
| "To this end, liver fibrosis was induced in AR+/+ and AR-/- mice by chronic CCl(4) administration." | ( Avila, MA; Berasain, C; Cartagena-Lirola, H; Castillo, J; Goñi, S; Latasa, MU; Lotersztajn, S; Nicou, A; Perugorria, MJ; Prieto, J; Vespasiani-Gentilucci, U; Zagami, MG, 2008) |
| "Endogenous alphaCGRP mitigates liver fibrosis in chronic hepatitis induced by repeated administration of Con A." | ( Ichikawa-Shindo, Y; Iinuma, N; Kamiyoshi, A; Kawate, H; Koyama, T; Muto, S; Sakurai, T; Shindo, T; Yoshizawa, T, 2009) |
| "CCl(4) induced liver fibrosis in rats, but no liver fibrosis was observed in rats treated with corn oil." | ( Fang, HL; Lin, WC, 2008) |
| "To induce liver fibrosis, rats were treated with thioacetamide for 7 weeks and administrated once with Ad-TbetaRIIDeltacyt or Ad-betagal through the iliac vein." | ( Arellano-Olivera, I; Armendariz-Borunda, J; Bueno-Topete, M; Gonzalez-Cuevas, J; Lucano-Landeros, S; Marquez-Aguirre, A; Navarro-Partida, J; Sandoval-Rodriguez, A, 2009) |
| "Sixty patients with schistosomal liver fibrosis were divided into treatment group and control group." | ( Ai, G; Huang, H; Huang, J; Huang, T; Jiao, Y; Li, L; Ma, K; Xiao, F; Yu, H, 2009) |
| "In ConA-induced chronic liver fibrosis model, accumulation of smooth-muscle actin (SMA)-expressing cells was partially inhibited by AS605240 treatment." | ( Chen, LJ; Chen, ZZ; He, CM; Hu, XH; Ke, J; Luo, YF; Peng, XD; Song, LF; Wang, YS; Wang, ZL; Wei, YQ; Wu, XH; Zhang, W, 2009) |
| "An immune liver fibrosis model of rat was established by administering human serum albumin (HSA)." | ( Duan, ZJ; Sun, YJ; Wang, F, 2009) |
| "There existed obvious liver fibrosis in liver tissues in the untreated group as compared with the blank group (P<0." | ( Chen, JM; Ji, G; Liu, T; Wang, L; Xing, LJ; Zheng, PY, 2009) |
| "Ace2 KO mice showed increased liver fibrosis following bile duct ligation for 21 days or chronic carbon tetrachloride (CCl(4)) treatment." | ( Brenner, DA; De Minicis, S; Kluwe, J; Kodama, Y; Osterreicher, CH; Oudit, GY; Penninger, JM; Penz-Osterreicher, M; Schuster, M; Seki, E; Taura, K, 2009) |
| "Whereas loss of ACE2 activity worsens liver fibrosis in chronic liver injury models, administration of recombinant ACE2 shows therapeutic potential." | ( Brenner, DA; De Minicis, S; Kluwe, J; Kodama, Y; Osterreicher, CH; Oudit, GY; Penninger, JM; Penz-Osterreicher, M; Schuster, M; Seki, E; Taura, K, 2009) |
| "Rats with advanced liver fibrosis due to prolonged bile duct ligation or carbon tetrachloride administration were treated with daily doses of saline, losartan-M6PHSA, M6PHSA or oral losartan during 3 days." | ( Arroyo, V; Bataller, R; Beljaars, L; Brenner, DA; Fondevila, C; Ginès, P; Gonzalo, T; Kok, RJ; Lacombe, M; Moreno, M; Poelstra, K; Prakash, J; Sancho-Bru, P; Swart, J; Temming, K; van Beuge, M; van der Hoeven, P, 2010) |
| "Eighty-four patients with liver cirrhosis were randomly divided into 2 groups:42 to the treatment group who were given oral capsules of Ursodeoxycholi acid combined with reduced glutathione,and the other 42 to the control group who received Yinzhihuang intravenously, combined with reduced glutathione." | ( Li, N; Li, Y; Shen, S; Wang, X, 2010) |
| "Treatment of liver fibrosis associated with Schistosoma japonicum ova-induced granulomas remains a challenging proposition." | ( Li, J; Li, X; Luo, Q; Peng, J; Shen, J; Wei, W; Wen, H; Zhong, Z, 2010) |
| "Sorafenib treatment attenuated liver fibrosis and was associated with a significant decrease in intrahepatic fibrogenesis, hydroxyproline accumulation and collagen deposition." | ( Gao, J; Jiang, H; Ma, J; Wang, Y; Zhang, D; Zhang, J, 2010) |
| "Following chronic CCl(4) administration, liver fibrosis was analyzed using Sirius Red staining with quantitative morphometry and real-time polymerase chain reaction (PCR) in MMP-2-/- mice and age-matched MMP-2+/+ controls." | ( Alvarez, CE; Bansal, MB; Bowles, R; DiFeo, A; Friedman, SL; Gupta, R; Martignetti, JA; Narla, G; Radbill, BD; Ramirez, MC; Saiman, Y; Vrabie, R, 2011) |
| "Taken together, VNP ameliorates liver fibrosis by inhibiting collagen production from hepatic stellate cells via guanylyl cyclase-coupled NPR/cGMP/PKG pathway, indicating that VNP might be a new effective reagent in the treatment of liver fibrosis." | ( Chen, BY; Qu, P; Tie, R; Yu, J; Zhu, MZ; Zhu, XX, 2010) |
| "Severe liver fibrosis is a rare event in patients treated with MTX and is probably unrelated to the total dose." | ( Chabrun, E; de Lédinghen, V; Doutre, MS; Laharie, D; Longy-Boursier, M; Pellegrin, JL; Schaeverbeke, T; Seneschal, J; Villars, S; Zerbib, F, 2010) |
| "Individuals naïve for interferon in whom liver fibrosis had been assessed using elastometry within the year before being treated were chosen." | ( Barreiro, P; González-Lahoz, J; Labarga, P; Martín-Carbonero, L; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2011) |
| "Treatment of liver fibrosis associated with Schistosoma japonicum ova-induced granulomas remains a challenging proposition." | ( Li, X; Luo, Q; Shen, J; Wei, W; Wen, H; Zhong, Z, 2009) |
| "None of the many HCV- and liver fibrosis-related parameters analysed showed a significant association with HIV-1 viral load or CD4 cell count in multivariate analyses, with the exception of the annual fibrosis progression index which almost reached statistical significance in the subgroup of ART-untreated patients (P=0." | ( Asensi, V; Cartón, JA; Collazos, J, 2011) |
| "Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce." | ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010) |
| "Liver samples from patients with liver fibrosis and from mice treated by either carbon tetrachloride (CCl(4)) or thioacetamide (TAA) were evaluated for mRNA expression of Snail1." | ( Brun, P; Buda, A; Castagliuolo, I; De Caro, R; Fabris, P; Giordani, MT; Grillo, AR; Macchi, V; Martines, D; Palù, G; Scarpa, M; Signori, S; Stefani, A, 2011) |
| "In the CCl(4)-induced liver fibrosis model, systemic administration of pMMP13 using HA and polyethylenimine (PEI) significantly increased the expression of MMP13 and reduced collagen deposition." | ( Cho, HJ; Kim, EJ; Kim, JY; Kim, YB; Oh, YK; Park, D; Park, TG; Shim, CK, 2011) |
| "Besides the staging of liver fibrosis, CMV co-infection should be considered as an extremely important factor when designing predictive models for HCV response to interferon treatment." | ( Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N, 2011) |
| "Patients with liver cirrhosis frequently undergo diagnostic or therapeutic upper GI endoscopy (UGIE), and the liver disease might impair the metabolism of drugs usually administered for sedation." | ( Bonilha, DQ; Brito, JR; Correia, LM; Ferrari, AP; Gomes, GF; Lenz, L; Libera, ED; Nakao, FS; Rohr, MR, 2011) |
| "Reversibility of liver fibrosis with immunosuppressive therapy (IT) has been described in autoimmune hepatitis (AIH)." | ( Brahm, J; Márquez, S; Poniachik, J; Smok, G; Valera, JM, 2011) |
| "There is a need for a new liver fibrosis model of immunodeficient mice to study the effects of cell therapy on liver disease because there are not many animal models available to study the effects of cell therapy." | ( Choi, HJ; Hyon, MK; Kang, BC; Kwon, E, 2011) |
| "Post-treatment liver biopsy showed liver cirrhosis, probably due to the interferon treatment itself." | ( Aoyagi, Y; Ikeda, H; Matsuda, Y; Morita, S; Nomoto, M; Ohkoshi, S; Takahashi, H; Takeuchi, M; Tanaka, Y; Yamagiwa, S; Yano, M, 2011) |
| "Obesity, IR, steatosis and liver cirrhosis were independent negative predictors of the response to the treatment with peginterferon alpha and ribavirin." | ( Abdurakhmanov, DT; Baĭzhanova, ZhZh; Ignatova, TM; Nekrasova, TP, 2011) |
| "Advanced liver fibrosis was induced in female mice by chronic administration of carbon tetrachloride." | ( Forbes, SJ; Gordon-Walker, TT; Hartland, S; Hume, DA; Iredale, JP; Pope, C; Ramachandran, P; Robson, AJ; Thomas, JA; Van Deemter, M; Wojtacha, D, 2011) |
| "In vivo, NA significantly attenuated liver fibrosis in TAA-treated rats as assessed by histological analysis using hematoxylin-eosin and Masson's trichrome staining." | ( Jang, JJ; Jin, J; Lee, KB; Park, SY, 2011) |
| "CCl4 treatment induced micronodular liver fibrosis with a pronounced deposition of collagen fibers." | ( Dong, H; Guo, J; Li, X; Liu, J; Niu, Y; Zhang, Y; Zhao, X; Zhou, L, 2011) |
| "To address this issue, we induced liver fibrosis by carbon tetrachloride (CCl(4)) chronic administration to 8-week- and 15-month-old mice." | ( Abdoun, E; Collin de l'Hortet, A; Cosson, C; Fromenty, B; Gilgenkrantz, H; Guidotti, JE; Mahrouf-Yorgov, M; Mitchell, C; Slama, A, 2011) |
| "CD34(+) cell transplantation reduced liver fibrosis in a dose-dependent fashion, with decreased collagen type-I and α-SMA-positive cells after 6 weeks of CCl(4) treatment by Mallory's Azan and immunohistochemical staining." | ( Abe, M; Asahara, T; Hashimoto, O; Ii, M; Iwamoto, H; Kawamoto, A; Koga, H; Masuda, H; Naitou, M; Nakamura, T; Sata, M; Torimura, T; Tsutsumi, V; Ueno, T, 2012) |
| "Using a mouse liver fibrosis model, we show that carbon tetrachloride treatment induces ADAMTS1 expression in parallel to that of type I collagen." | ( Baffet, G; Bonnier, D; Bourd-Boittin, K; Ezan, F; Leyme, A; Mari, B; Samson, M; Theret, N; Tuffery, P, 2011) |
| "Patients with HCV liver cirrhosis are a category difficult to treat." | ( Bota, S; Danila, M; Neghina, AM; Popescu, A; Sirli, R; Sporea, I; Strain, M, 2011) |
| "More patients with liver fibrosis failed to respond to treatment compared to patients without fibrosis, a difference bordering on statistical significance (60% vs." | ( Berlot, AH; Efe, C; Kav, T; Muratori, P; Ozaslan, E; Ozkayar, O; Purnak, T; Shorbagi, A; Sökmensuer, C, 2012) |
| "The presence of liver fibrosis may increase the likelihood of treatment failure as well as the risk of developing side effects." | ( Berlot, AH; Efe, C; Kav, T; Muratori, P; Ozaslan, E; Ozkayar, O; Purnak, T; Shorbagi, A; Sökmensuer, C, 2012) |
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "To evaluate the presence of significant liver fibrosis by transient elastography (FibroScan®) in IBD patients treated with methotrexate." | ( Algaba, A; Barbero-Villares, A; Bermejo, F; Gisbert, JP; López-Sanromán, A; Maté, J; Mendoza Jiménez-Ridruejo, J; Mendoza, JL; Moreno-Otero, R; Pajares, R; Pérez-Calle, JL; Taxonera, C, 2012) |
| "(1) Development of advanced liver fibrosis in IBD patients treated with methotrexate is exceptional." | ( Algaba, A; Barbero-Villares, A; Bermejo, F; Gisbert, JP; López-Sanromán, A; Maté, J; Mendoza Jiménez-Ridruejo, J; Mendoza, JL; Moreno-Otero, R; Pajares, R; Pérez-Calle, JL; Taxonera, C, 2012) |
| "Forty-nine hepatitis C patients with liver cirrhosis who were unable to use antiviral therapy because of hypersplenism were recruited for study and treated with splenectomy or partial splenic embolization." | ( Bai, XF; Hao, CQ; Jia, ZS; Kang, WZ; Li, B; Ma, L; Pan, L; Peng, XJ; Wei, X; Xie, YM; Zhang, Y, 2012) |
| "Sixty Wistar rats were used to construct liver fibrosis models and were randomly divided into 5 groups: group A (normal, untreated), group B (model for 4 wk, untreated), group C (model for 6 wk, untreated), group D [model for 6 wk, treated with zinc protoporphyrin IX (ZnPP-IX) from week 4 to week 6], group E (model for 6 wk, treated with hemin from week 4 to week 6)." | ( Wang, Y; Yang, H; Zhang, L; Zhao, JJ; Zhao, LF; Zhao, ZF, 2012) |
| "Medicinal treatment of liver fibrosis is still unsolved." | ( Alberti, A, 2012) |
| "The severity of liver fibrosis is known to be a good indicator for surveillance, and for determining the prognosis and optimal treatment of non-alcoholic steatohepatitis (NASH)." | ( Aoki, K; Bando, Y; Enomoto, H; Kanehara, H; Kasayama, S; Koga, M; Nakamura, H; Nakasho, K; Nishiguchi, SH; Notsumata, K; Tanaka, N; Toya, D, 2012) |
| "Both the difference of liver fibrosis indexes between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P < 0." | ( Chang, Y; Zhang, L, 2012) |
| "Both the difference of liver fibrosis indexes between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P < 0." | ( Chang, Y; Zhang, L, 2012) |
| "Although our patient had liver cirrhosis (Child-Pugh classification B), no hepatic decompensation was developed during the treatment course of posaconazole." | ( Chang, YT; Chen, CY; Chen, TC; Chen, YH; Huang, CH; Lai, CC; Lin, CY; Lin, SY; Lin, WR; Lu, PL; Tsai, KB, 2012) |
| "To investigate liver fibrosis, TGF-?1 levels and curative effects on hepatocellular carcinoma (HCC) with small and conventional dose perfusion chemotherapy by transcatheter arterial chemo embolization (TACE)." | ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012) |
| "To induce liver fibrosis, wild-type (WT) and SOD1mu mice were treated with CCl(4) or bile duct ligation (BDL)." | ( Aoyama, T; Brenner, DA; Fioraso-Cartier, L; Gaggini, F; Heitz, F; Laleu, B; Merlot, C; Molango, S; Page, P; Paik, YH; Szyndralewiez, C; Watanabe, S, 2012) |
| "Patients with high viremia, liver cirrhosis, rituximab treatment, and distant metastasis are at high risk of prophylactic failure and need antiviral agents with a greater barrier to resistance." | ( Kim, BG; Kim, D; Kim, IK; Kim, W; Kim, YJ; Lee, HS; Yoon, JH, 2012) |
| "The coexistence of liver cirrhosis with hepatocellular carcinoma (HCC) and colon cancer (Ca), which is a rare clinical condition, was treated in a liver transplant recipient." | ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "We present a patient with autoimmune liver cirrhosis who was intolerant of corticosteroid and azathioprine, who was successfully treated with cyclosporine." | ( Jaganathan, V; Sanjiv, M; Wah-Kheong, C, 2012) |
| "The results showed that serum albumin, liver fibrosis and liver function were significantly improved in the group treated with cultured bone marrow cells (P<0." | ( Hisanaga, T; Iwamoto, T; Sakaida, I; Takami, T; Terai, S; Watanabe, S; Yamamoto, N, 2013) |
| "To induce different stages of liver fibrosis, a sufficient number of male Wistar rats were differentially exposed to chronic administration with carbon tetrachloride." | ( Acevedo-García, C; Aguirre-García, J; de la Rosa, JM; Escobedo, G; Fabila, D; Guzmán, C; Kershenobich, D; López-Navarrete, G; Moreno, E; Stolik, S; Suárez-Álvarez, K, 2012) |
| "PF administration attenuated DMN-induced liver fibrosis at least in part by regulating macrophage disruption in the main organs." | ( Chen, X; Liu, C; Lu, L; Lu, Y; Lv, Z; Pan, Q; Xu, Q; Yang, Z, 2012) |
| "Among patients with liver cirrhosis (482 entecavir-treated, 69 treatment-naïve), entecavir-treated patients had reduced risks of all clinical outcomes when compared with treatment-naïve patients with cirrhosis after adjusted for model for end-stage liver disease score: hepatic events (hazard ratio [HR], 0." | ( Chan, HL; Chan, HY; Ip, ZM; Iu, HW; Lai, JW; Lam, AT; Lee, SK; Leung, JM; Lo, AO; Mak, CW; Wong, GL; Wong, VW, 2013) |
| "Two models of rat liver fibrosis, the carbon tetrachloride and bile duct ligation models, were treated with rAAV/siRNA-TIMP-1." | ( Bai, Y; Chen, J; Cong, M; Cong, R; Fan, X; Jia, J; Li, H; Liu, T; Peng, Z; Tang, S; Tong, X; Wang, B; Wang, P; Wu, P; Yang, A; You, H, 2013) |
| "DMN treatment for 4 weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and collagen content." | ( Choi, CY; Choi, JH; Chung, YC; Hwang, YP; Jeong, HG; Jin, SW; Khanal, T; Kim, HG; Lee, KJ; Lee, YC, 2013) |
| "Splenectomy is a recognized therapy for liver cirrhosis with splenomegaly, since it decreases free iron concentration that accompanies the destruction of red blood cells." | ( Du, JL; Duan, ZJ; Guo, SB; Liu, Z; Sun, XY; Wang, QM, 2013) |
| "Analysis of MSC and IL-6 treatment on liver fibrosis was measured by histopathology, PAS, TUNEL and Sirius red staining, RT-PCR, and liver function tests for Bilirubin and Alkaline Phosphatase (ALP)." | ( Ali, G; Khan, M; Khan, SN; Mohsin, S; Nasir, GA; Riazuddin, S; Shams, S, 2013) |
| "We aimed to evaluate the presence of liver fibrosis identified by transient elastography (TE), its relationships with indirect biochemical markers [the aspartate aminotransferase/platelet ratio index (APRI), the Forns index and FIB-4] and its predictive factors in HIV-monoinfected patients receiving antiretroviral therapy (ART)." | ( Bagaglio, S; Carbone, A; Castagna, A; Galli, L; Gallotta, G; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Salpietro, S; Uberti-Foppa, C, 2013) |
| "Diagnosis and therapy of early stage liver fibrosis is very important for the treatment of fatal liver diseases." | ( Akaike, T; Chung, BH; Goto, M; Ise, H; Kim, E; Kim, SJ, 2013) |
| "The liver function indexes and liver fibrosis indexes were significantly improved after treatment (P<0." | ( Liang, XL; Yuan, JY, 2013) |
| "In HBV-related decompensated liver cirrhosis patients, the combined de novo LAM and ADV therapy is more efficacious and safer compared to LAM alone." | ( Chen, Y; Li, LJ; Lv, GC; Sheng, JF; Yang, YD; Yao, JM; Zheng, L, 2013) |
| "IFN-α can inhibit liver fibrosis following 6 weeks of middle-dose IFN-α therapy by upregulating CD4(+)CD25(+)Foxp3(+) Tregs and suppressing CD8(+) T cells." | ( Cao, YM; Feng, L; Kang, H; Liu, LN, 2013) |
| "SVR according to the stage of liver fibrosis assessed by pretreatment liver biopsy and genotype results were analyzed." | ( Kang, EJ; Kweon, YO; Lee, HS; Lee, YL; Park, HW; Park, SY; Tak, WY; Yang, HM, 2013) |
| "In the treatment group, the indicator of liver fibrosis, CIV improved and the 2 indicators of liver fibrosis, PIIIP and HA improved significantly, but the indicators of serum enzyme activities did not improve." | ( Guo, WJ; Hong, Y; Hua, HY; Liu, M; Lu, P; Niu, XH; Wu, PF; Zhang, HF; Zhang, Y, 2013) |
| "STS is effective in the treatment of liver fibrosis of advanced schistosomiasis." | ( Guo, WJ; Hong, Y; Hua, HY; Liu, M; Lu, P; Niu, XH; Wu, PF; Zhang, HF; Zhang, Y, 2013) |
| "In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects." | ( Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S, 2013) |
| "Thus, using HGF in gene therapy against liver fibrosis is an attractive approach." | ( Li, WY; Wen, KM; Wu, W; Zhang, SH; Zhao, JN, 2013) |
| "Advanced liver fibrosis is a recognized barrier to both access and response to triple therapy with protease inhibitors Boceprevir and Telaprevir, and is associated with an increased risk of severe treatment-related adverse events." | ( Colombo, M; D'Ambrosio, R, 2013) |
| "In this model of toxin-induced liver fibrosis, treatment with two galectin protein inhibitors with different chemical compositions significantly reduced fibrosis, reversed cirrhosis, reduced galectin-3 expressing portal and septal macrophages, and reduced portal pressure." | ( Chou, H; Fiel, MI; Friedman, SL; Hong, F; Klyosov, A; Traber, PG; Zomer, E, 2013) |
| "Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1·8 mg od." | ( Abouda, G; Atkin, SL; Coady, AM; Kahal, H; Kilpatrick, ES; Rigby, AS, 2014) |
| "This study confirms that the rate of liver fibrosis regression increases during the follow-up after SVR to interferon therapy in HIV-/HCV-coinfected patients." | ( Casado, JL; Martí-Belda, P; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C, 2013) |
| "CCl4-induced chronic liver fibrosis model in mice was established and activated rat hepatic stellate cell was treated with BBR." | ( Chen, L; Guan, F; Kan, M; Li, J; Pan, Y; Wang, Y; Xiao, X; Zhang, X, 2014) |
| "Both treatments effectively reduced liver fibrosis at age 16 months, consistent with markedly inhibited transition of hepatic stellate cells into myofibroblasts, the central event in the process of liver fibrosis." | ( Brooks, ED; Fyfe, JC; Kishnani, PS; Sun, B; Thurberg, BL; Yi, H, 2014) |
| "Extent of liver fibrosis is one of the most important factors in determining prognosis and the need for active treatment in chronic hepatitis B (CHB)." | ( Brcic, M; Hauser, G; Jovanovic, P; Salkic, NN, 2014) |
| "Several hallmarks of liver fibrosis are influenced by S1P, and the interference of S1P signaling by treatment with FTY720 results in beneficial effects in various animal models of fibrosis." | ( Kong, Y; Tang, N; Wang, H; Wang, S, 2014) |
| "In vivo, we induced liver fibrosis by bile duct ligation (BDL), chronic carbon tetrachloride (CCl4), and chronic thioacetamide (TAA) administration." | ( Banini, BA; Kim, TH; Mikhail, DS; Moser, CD; Nakamura, I; Roberts, LR; Shaleh, HM; Thornburgh, SR; Walters, I; Yang, JD; Zakharia, K, 2014) |
| "The accurate staging of liver fibrosis is of paramount importance to determine the state of disease progression, therapy responses, and to optimize disease treatment strategies." | ( Csucs, G; Peng, Q; So, PT; Stanciu, GA; Stanciu, SG; Welsch, RE; Xu, S; Yan, J; Yu, H, 2014) |
| "A total of 430 patients with CHB-related liver fibrosis were randomly assigned to treatment groups for receipt of a 12-month course of the antiviral drug entecavir alone (control group) or in combination with the TCM Liuweiwuling tablets." | ( An, J; Ni, W; Qiao, J, 2014) |
| "After treatment, the degrees of liver fibrosis in groups A, B and C decreased." | ( Chen, Y; Xiao, Z, 2013) |
| "Progressive liver fibrosis was induced by repeated intraperitoneal administration of dimethylnitrosamine (DMN) for 3 wk." | ( Endo, K; Hori, T; Iwaisako, K; Jobara, K; Kaido, T; Uchida, Y; Uemoto, S, 2014) |
| "In HCV genotype 1 infection and F3 or F4 liver fibrosis, treatment with boceprevir or telaprevir in addition to pegylated interferon and ribavirin is recommended." | ( Begovac, J, 2013) |
| "In addition, JWXYS treatment prevented liver fibrosis induced by DMN." | ( Chang, JC; Chang, WC; Chang, WP; Chien, SC; Hsu, SC; Lin, CH; Lin, PH; Pei, JK; Wu, YC, 2014) |
| "To establish the role of liver fibrosis as a predictive tool of response to pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) treatment in human immunodeficiency (HIV)/hepatitis C virus (HCV) coinfected patients, in addition to recognized predictive factors (HCV load, HCV genotype, IL-28B polymorphism)." | ( Corchado, S; Girón-González, JA; López-Cortés, LF; Márquez-Coello, M; Rivero, A; Rivero-Juárez, A; Torres-Cornejo, A, 2014) |
| "Advanced liver fibrosis results in cirrhosis and liver failure, and liver transplantation is often the only option for effective therapy; however, the shortage of available donor livers limits this treatment." | ( Chen, YH; Cheng, PJ; Cheng, WT; Chou, CJ; Kao, YJ; Ko, IC; Peng, SY; Shaw, SW; Wu, SC, 2014) |
| "To generate liver fibrosis models, male ICR mice were treated with CCl4 via oral gavage for 4 weeks, and the serum levels of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, and albumin were higher than in the control group following chemical induction." | ( Chen, YH; Cheng, PJ; Cheng, WT; Chou, CJ; Kao, YJ; Ko, IC; Peng, SY; Shaw, SW; Wu, SC, 2014) |
| "These novel markers of liver fibrosis remodeling may help to monitor the hepatic effects by HIV therapy." | ( Anadol, E; Bendtsen, F; Boesecke, C; Byrjalsen, I; Karsdal, MA; Krag, A; Leeming, DJ; Møller, S; Nielsen, MJ; Rockstroh, J; Schierwagen, R; Schwarzer-Zander, C; Spengler, U; Strassburg, CP; Trebicka, JK, 2014) |
| "Assessing the severity of liver fibrosis has direct clinical implications for patient diagnosis and treatment." | ( Fuentes-Orrego, JM; Ghosh, A; Lamb, P; Mendonça, PR; Patino, M; Sahani, DV, 2015) |
| "The percentage area of liver fibrosis was also significantly reduced in GTN-treated mice (5." | ( Boudechiche, L; Branchereau, S; Dagher, I; Davit-Spraul, A; Groyer-Picard, MT; Hadchouel, M; Laïnas, P; Tranchart, H; Weber, A, 2015) |
| "The goal of imaging liver cirrhosis is the early identification of high-grade dysplastic nodules/early HCC since their treatment is associated with a higher chance of radical cure and lower recurrence rates." | ( Ascanio, S; Garzillo, G; Golfieri, R; Renzulli, M, 2014) |
| "In this study, liver fibrosis was induced by CCl4 in treated rats." | ( Gong, M; He, X; Hu, Y; Li, R; Luo, S; Ma, X; Wang, J; Wang, R; Xiao, X; Zhang, P; Zhao, Y, 2014) |
| "The degree of liver fibrosis did not appear to affect the probability of achieving SVR12 following treatment with the interferon-free regimen of faldaprevir, deleobuvir, and ribavirin." | ( Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S, 2015) |
| "Seventy-three patients with liver cirrhosis (LC) and advanced HCC (aHCC) received hepatic arterial infusion chemotherapy (HAIC: leucovorin (LV) at 12 mg/h, cisplatin (CDDP) at 10 mg/h and 5-fluorouracil (5-FU) at 250 mg/22 h) via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneous drug delivery system." | ( Matsui, D; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y, 2015) |
| "Splanchnic angiogenesis in liver cirrhosis often leads to complications as gastroesophageal variceal hemorrhage and the treatment efficacy is adversely affected by poor portal-systemic collateral vasoresponsiveness related to nitric oxide (NO)." | ( Chuang, CL; Huang, HC; Huo, TI; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Tsai, MH; Tung, HC; Wang, SS, 2015) |
| "XYXD treatment reduced CCl4-induced liver fibrosis and decreased hepatic hydroxyproline (Hyp) content, the mRNA levels of smooth muscle actin (α-SMA) and Col 1(α1) in fibrotic liver." | ( Cheng, Z; Dai, X; Liu, C; Sheng, X; Tao, L; Xue, D; Yuan, X, 2015) |
| "XYXD treatment attenuates liver fibrosis by inhibiting HSC activation via inhibition of NF-κB and TGF-β1 signaling pathway, thereby blocking the synthesis of Col1 (α1) and TIMP-1." | ( Cheng, Z; Dai, X; Liu, C; Sheng, X; Tao, L; Xue, D; Yuan, X, 2015) |
| "Key Messages: In patients with advanced liver fibrosis or liver cirrhosis, antiviral therapy is mandatory to slow down, halt or reverse disease progression and possibly reduce the risk of HCC development." | ( Boettler, T; Thimme, R, 2015) |
| "For chronic HBV carrier liver cirrhosis patients, a successful vaccine response can only be achieved in selected patients, such as those treated with experimentally reduced immunosuppression protocols." | ( Takaki, A; Yagi, T; Yasunaka, T, 2015) |
| "Substantial liver fibrosis on SWE was observed in about 5% of MTX-treated patients with RA and was associated with only a high body mass index but not with the cumulative MTX dose, suggesting that other comorbidities might have a more important role in liver fibrosis." | ( Bang, SY; Jeong, WK; Kim, JY; Kim, MY; Kim, TY; Kim, Y; Lee, HS; Sohn, JH, 2015) |
| "114 patients with liver cirrhosis have been treated at the Department of Faculty Surgery of I." | ( Chernousov, AF; Karpova, RV; Khorobrykh, TV, 2015) |
| "Although liver fibrosis is reversible, no effective drug therapy is available to prevent or reverse HSC activation." | ( Faber, KN; Heegsma, J; Laliena, A; Moshage, H; Shajari, S; Tuñón, MJ, 2015) |
| "In the treatment group, liver fibrosis significantly decreased compared to the model group (P < 0." | ( Lv, HY; Wang, YL; Zhang, Q, 2015) |
| "Significant liver fibrosis remains an impediment to achieving SVR with short-duration DAA therapy." | ( Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Lam, B; Masur, H; McLaughlin, M; McManus, M; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Shrivastava, S; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E, 2016) |
| "Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker useful for predicting the efficacy of DAA-based triple therapy for chronic hepatitis C patients." | ( Furusyo, N; Hayashi, J; Hayashi, T; Mukae, H; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K; Ura, K, 2016) |
| "An advanced liver fibrosis model was developed using C3H/HeN mice subjected to 20 weeks of prolonged TAA/ethanol weight-adapted treatment." | ( Jeong, YY; Kim, JH; Lee, JH; Moon, MJ; Thomas, RG, 2015) |
| "Liver fibrosis leads to liver cirrhosis and failure, and no effective treatment is currently available." | ( Hong, JM; Kang, JW; Lee, SM, 2016) |
| "In patients with liver fibrosis (n = 8) the change in T2* following O2 administration was elevated (0." | ( Bowden, DJ; Graves, MJ; Lomas, DJ; Patterson, AJ; Patterson, I; Priest, AN; Wallace, TE, 2016) |
| "Chronic immune activation and liver fibrosis remain important obstacles for highly active antiretroviral therapy success." | ( Cappon, A; Del Cornò, M; Donninelli, G; Gessani, S; Marra, F; Varano, B, 2016) |
| "Recent studies suggest that liver cirrhosis is reversible after administering oral nucleos(t)ide analogue therapy to patients with hepatitis B virus (HBV) infection." | ( Boo, SJ; Cho, YK; Choi, EK; Jeong, SU; Jwa, HY; Kim, BS; Kim, HU; Lee, BW; Na, SY; Song, BC; Song, HJ, 2016) |
| "However, advanced liver fibrosis and HIV coinfection were significantly associated with treatment failure." | ( Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A, 2017) |
| "Sprague-Dawley rats liver fibrosis was generated by 12-weeks treatment with CCl4 intraperitoneal injection." | ( Deng, ZY; Hu, W; Li, J; Liu, LP; Shi, P; Tao, H; Yang, JJ, 2016) |
| "If metformin is effective in reducing liver fibrosis in this patient population, this will represent a well-tolerated, easy-to-administer, inexpensive therapy that will protect against negative HCV outcomes." | ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "In a liver fibrosis treatment model, when shikonin was continuously injected intraperitoneally at a dose of 1mgkg(-1) over a two-week period, the hydroxyproline content in the mice plasma was significantly reduced and the degree of liver fibrosis was decreased significantly." | ( Han, T; Ma, T; Yan, D; Yang, H; Ye, Z; Zhang, G, 2016) |
| "Despite efforts to develop treatment for liver fibrosis, there are no approved agents as anti-fibrotic drugs to date." | ( Bae, SJ; Choi, J; Kim, KW; Kim, SW; Lee, HS; Park, JH; Seo, JH; Shin, HS; Son, T; Wee, HJ, 2016) |
| "Patients with compensated liver cirrhosis have similar virological response and tolerance for daclatasvir plus asunaprevir therapy to patients with chronic hepatitis." | ( Aikata, H; Chayama, K; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Ochi, H; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S, 2017) |
| "Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 months." | ( Andreone, P; Beuers, U; Bowlus, C; Drenth, JP; Floreani, A; Hansen, B; Hirschfield, GM; Hohenester, S; Hooshmand-Rad, R; Invernizzi, P; Jones, DE; Kowdley, KV; Lindor, KD; Luketic, V; MacConell, L; Marmon, T; Marschall, HU; Mazzella, G; Nevens, F; Pencek, R; Pockros, PJ; Pruzanski, M; Regula, J; Shah, H; Shapiro, D; Sheeron, S; Shiffman, M; Strasser, SI; Trauner, M; van Erpecum, KJ; Vargas, V; Vincent, C, 2016) |
| "Briefly, a rat model of liver fibrosis was created by administering intraperitoneal injections of CCl4." | ( Chi, C; Cui, LJ; Hou, F; Li, CY; Liu, RX; Liu, XY; Wen, Y; Yi, E; Yin, CH, 2016) |
| "144/260 were pre-treated, 89/260 had liver cirrhosis, 56/260 had portal hypertension with platelets < 100/nL, 25/260 had a MELD score ≥ 10 and 17/260 were post-liver transplantation patients." | ( Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR, 2016) |
| "Excessive accumulation of body iron in liver cirrhosis is an important predictor of liver failure and available data suggest that it can be considered as target for adjuvant therapy in this condition." | ( Bernat, A; Sikorska, K; Wroblewska, A, 2016) |
| "It is thus crucial that liver cirrhosis and HE are managed aggressively to try and lower the need for transplantation and other aggressive treatment measures." | ( Allampati, S; Mullen, KD, 2016) |
| "There are no approved treatments for liver fibrosis." | ( Byrjalsen, I; Christiansen, C; Gardner, S; Goodman, Z; Henriksen, K; Karsdal, MA; Krag, A; Leeming, DJ; Nielsen, MJ; Patel, K; Schuppan, D, 2016) |
| "BPA administration induced liver fibrosis as reflected in an increase in serum hepatic enzymes activities, hepatic hydroxyproline content and histopathological changes particularly increased collagen fibre deposition around the portal tract." | ( Abdallah, FR; Atteia, HH; Elswefy, SE; Hasan, RA; Wahba, AS, 2016) |
| "Two of them had liver cirrhosis and one had hepatocellular carcinoma postcurative therapy." | ( Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH, 2017) |
| "This study aims to investigate the liver fibrosis in mice induced by long-term APAP treatment and the involvement of early growth response 1 (Egr-1)." | ( Bai, Q; Ji, L; Jin, Y; Sheng, Y; Shi, L; Wang, Z; Yan, H, 2017) |
| "A 56-year-old Japanese man with liver cirrhosis (LC) due to hepatitis C virus was admitted to our hospital for radiofrequency ablation of residual tumor following lusutrombopag administration." | ( Abe, S; Kamimura, K; Kawai, H; Sakamaki, A; Takamura, M; Terai, S; Tsuchiya, A; Watanabe, T; Yamagiwa, S, 2017) |
| "Although liver fibrosis is a major public health issue, there is still no effective drug therapy in the clinic." | ( Bi, Q; Huang, L; Li, C; Li, Z; Liu, S; Shen, Q; Xie, J, 2017) |
| "In vivo liver fibrosis in mice was induced by intraperitoneally injections of CCl4 for eight weeks, and in vitro studies were performed on activated LX2 cells treated with transforming growth factor-β (TGF-β)." | ( Hao, C; Jianping, G; Xuanfei, L; Yanming, L; Zhujun, Y, 2017) |
| "Patients with liver cirrhosis have been excluded from randomized clinical trials of oral anticoagulation therapy for stroke prevention in atrial fibrillation." | ( Chang, SL; Chao, TF; Chen, SA; Chen, TJ; Chung, FP; Hu, YF; Kuo, L; Liao, JN; Lin, YJ; Lip, GYH; Liu, CJ; Lo, LW; Tuan, TC, 2017) |
| "For atrial fibrillation patients with liver cirrhosis in the current analysis of an observational study, warfarin use was associated with a lower risk of ischemic stroke and a positive net clinical benefit compared with nontreatment, and thus, thromboprophylaxis should be considered for such patients." | ( Chang, SL; Chao, TF; Chen, SA; Chen, TJ; Chung, FP; Hu, YF; Kuo, L; Liao, JN; Lin, YJ; Lip, GYH; Liu, CJ; Lo, LW; Tuan, TC, 2017) |
| "We can expect prognostic improvement of liver cirrhosis by warfarin following two-week DS therapy for the treatment of PVT in patients with liver cirrhosis safety and effectiveness." | ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2017) |
| "Murine liver fibrosis was developed by CCI4 treatment three times per week over a 6-week period." | ( Liu, C; Ma, W; Tao, L; Xue, D; Zhang, J; Zhang, W; Zhu, Y, 2017) |
| "However, the association of T2DM with liver cirrhosis and therapy response in HCC patients is not clear." | ( Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A, 2018) |
| "This case of a patient with liver cirrhosis secondary to autoimmune liver disease with episodes of bleeding from esophageal varices is the first documented case in which a treatment with a PDE-5-inhibitor for eight years was monitored." | ( Deibert, P; Kreisel, W; Lazaro, A; Rössle, M; Schaffner, D; Stankovic, Z, 2018) |
| "We reported a case of Child's class C liver cirrhosis, in which lactic acidosis, an adverse effect related to prolonged use, occurred only after two weeks of linezolid treatment." | ( Cheng, CN; Lin, SW; Wu, CC, 2018) |
| "Although BMSC administration reduced liver fibrosis, transplantation of BMSCs/MMP1 enhanced the reduction of liver fibrosis to a higher level." | ( Du, C; Jiang, M; Qin, J; Wang, Y; Wei, X; Xu, H; Xue, H; Zeng, W; Zhang, Y; Zheng, S; Zhou, D, 2018) |
| "The alleviation of liver fibrosis with curcumin treatment was associated with a reduction of CXCL12, CXCR4, α-SMA and RhoA." | ( Huang, L; Qin, J; Qin, L; Yang, Q; Zhen, X, 2018) |
| "Application to patients with liver fibrosis and a personalized treatment is tightly linked to the development of noninvasive biomarkers of fibrosis, fibrogenesis and fibrolysis." | ( Ashfaq-Khan, M; Kim, YO; Schuppan, D; Yang, AT, 2018) |
| "Moderate to advanced liver fibrosis in HBV-mono-infection may well indicate poor access to screening and treatment of HBV infection." | ( Andersson, MI; Arends, JE; Glashoff, RH; Maponga, TG; Preiser, W; Taljaard, J; van Rensburg, CJ, 2018) |
| "So far, liver fibrosis still has no clinically-approved treatment." | ( El-Hadidy, WF; El-Khatib, AS; El-Mezayen, NS; El-Refaie, WM; Khattab, MM; Shalaby, TI, 2018) |
| "Advanced liver fibrosis affects the virological response to sofosbuvir-based therapy." | ( Aikata, H; Arataki, K; Chayama, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Imamura, M; Ito, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Miki, D; Morio, K; Morio, R; Moriya, T; Murakami, E; Nakahara, T; Nakamura, T; Nakamura, Y; Ochi, H; Tamura, T; Tsuge, M; Tsuji, K; Waki, K, 2018) |
| "A rat model of liver fibrosis was generated by administering CCl4 via subcutaneous injection twice a week for 12 weeks." | ( Liu, F; Ma, Z; Qian, J; Wu, G; Zhang, J, 2018) |
| "After the treatment, liver fibrosis scores of apartate aminotransferase to platelet ratio index (2." | ( Chen, EQ; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wu, DB; Zhang, DM, 2019) |
| "This study aims to investigate the liver fibrosis induced by long-term DB treatment in mice." | ( Guan, H; Ji, L; Miao, H; Wang, C; Wang, Z; Zhang, Y, 2019) |
| "CCl4 or alcohol treatment alone induced liver fibrosis or steatohepatitis, respectively, findings that were consistent with expected pathology." | ( Argemi, J; Bataller, R; Cichocki, JA; Dreval, K; Fukushima, H; Furuya, S; Katou, Y; Konganti, K; Kono, H; Pogribny, IP; Rusyn, I; Uehara, T, 2019) |
| "Staging of liver fibrosis is critical in guiding the treatment of chronic hepatitis B (CHB) virus." | ( Gu, J; Hu, J; Li, L; Yang, M; Zhang, X; Zhao, H, 2019) |
| "Eight patients reduced liver fibrosis stage during treatment, seven of whom were in the diacerein group (p = 0." | ( Cardoso, CRL; Carlos, FO; Leite, NC; Salles, GF; Viegas, BB; Villela-Nogueira, CA, 2019) |
| "Noninvasive early detection of liver cirrhosis and fibrosis is essential for management and therapy." | ( Denecke, T; Geisel, D; Haase, M; Hamm, B; Lüdemann, L; Schmelzle, M; Stief, JD; Theilig, D, 2019) |
| "The understanding of the pathogenesis of liver fibrosis has grown considerably, but the effective treatments are still lacking." | ( Cui, S; Field, RA; Li, J; Sun, D; Wang, G; Zang, Y; Zhang, H, 2019) |
| "In the BDL model, liver fibrosis and Kuppfer cell numbers were increased in IL-1Ra KO mice compared to wild type mice and wild type mice treated with IL-1Ra." | ( Balaphas, A; Buhler, LH; Clément, S; Lacotte, S; Meier, RPH; Meyer, J; Montanari, E; Morel, P; Muller, YD; Negro, F; Toso, C, 2019) |
| "Induction of liver fibrosis in TAA-treated rats was observed as evidenced by the biochemical and histopathological findings." | ( Abdel Rahman, RF; Arbid, MS; Badawi, M; El Awdan, SA; El Marasy, SA; Hegazy, RR; Ibrahim, HM, 2019) |
| "Patients requiring antiviral therapy (liver fibrosis stage ≥ F2, METAVIR scoring system) were treated with ETV for at least 5 years." | ( Chang, M; Guo, J; Hao, H; Hu, L; Li, M; Liu, R; Lu, Y; Shen, G; Wu, S; Xie, Y; Zhang, L, 2019) |
| "However, patients with liver cirrhosis infected by GT3 remain the most-difficult-to-treat group." | ( Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019) |
| "In addition, the increase of liver fibrosis, serum transaminase levels, as well as lipid peroxidation have been observed in mice co-treated with BDE-47 and HFD." | ( Cai, Z; Chung, ACK; Kang, Q; Lee, HK; Li, D; Yang, C; Zhu, L, 2019) |
| "In the present study we assessed whether liver fibrosis and cirrhosis can be reversed by treatment with MSCs or fibroblasts concomitant to partial hepatectomy (pHx)-induced liver regeneration." | ( Barnhoorn, MC; Coenraad, MJ; de Jonge-Muller, ESM; Hawinkels, LJAC; Molendijk, I; van der Helm, D; van Hoek, B; Verspaget, HW, 2019) |
| "In the treatment of GVB with liver cirrhosis, compared with the traditional sandwich method, the modified sandwich method was associated with a higher GV remission rate (RR: 1." | ( Gou, Y; He, S; Song, Q; Wu, K, 2019) |
| "PZQ exhibited a strong efficacy against liver fibrosis by inhibiting activation of HSCs via Smad7 up-regulation, suggesting potential broad utility in treatment of diseases characterized by liver fibrosis." | ( Kong, D; Liu, J; Liu, X; Lu, Z; Qiu, J; Wang, Y; Xie, Y; Zhang, R; Zhou, C, 2019) |
| "Restorative actions against alcoholic liver fibrosis were observed after oral administration of Asta-lipo for 4 weeks." | ( Huang, HH; Kuo, SM; Manousakas, I; Wu, YC; Wu, YJ; Yang, CC, 2019) |
| "Significant liver fibrosis was diagnosed in 4 patients in the MTX-treated RA (highest kPa value = 7." | ( Cadoni, ML; Carru, C; Castagna, F; Erre, GL; Mangoni, AA; Meloni, P; Passiu, G; Piga, M; Vidili, G; Zinellu, A, 2019) |
| "Non-invasive evaluation for liver fibrosis is clinically important, especially in patients with undetectable hepatitis B virus (HBV) DNA treated with nucleoside analogs." | ( Bai, WL; Chang, XJ; Chen, D; Chen, Y; Chen, YP; Dong, Z; Du, WJ; Jiang, QY; Li, Q; Li, XD; Li, YY; Li, ZQ; Liao, H; Sun, C; Sun, LJ; Wang, XD; Xu, DP; Yang, YP; Yu, ZJ; Zhang, CH, 2019) |
| "PS-induced liver fibrosis development was also drastically suppressed by treatment with either agent, and the combination of both reciprocally enhanced the antifibrotic effect." | ( Akahane, T; Fujinaga, Y; Kaji, K; Kawaratani, H; Kaya, D; Kitagawa, K; Moriya, K; Namisaki, T; Ozutsumi, T; Takaya, H; Tsuji, Y; Yamashita, S; Yoshiji, H, 2019) |
| "Collectively, celastrol attenuated liver fibrosis mainly through inhibition of inflammation by activating AMPK-SIRT3 signalling, which makes celastrol be a potential candidate compound in treating or protecting against liver fibrosis." | ( Chen, C; Duanmu, J; Gu, J; Li, C; Liu, Z; Miao, J; Tao, J; Tu, M; Wang, Y; Xiong, B; Yao, W; Zhao, L, 2020) |
| "To assess liver fibrosis by SWE before and after direct-acting antiviral treatment of chronic hepatitis C (CHC), we enrolled 165 CHC genotype 4 Egyptian patients treated with different Sofosbuvir-based regimens." | ( Abdelkareem, M; Abozeid, M; Akl, M; Elsakhawy, M; Fayoumi, AE; Kohla, MAS; Waheed, S, 2020) |
| "All mice administered oral DEN developed liver fibrosis, liver cirrhosis and hepatocellular carcinoma (HCC)." | ( Bai, L; Chen, Q; Jiang, S; Lai, J; Yang, W; You, X; Zhang, H, 2020) |
| "Patients with cirrhosis, advanced liver fibrosis and severe extrahepatic manifestations were enrolled in the treatment program." | ( Abutidze, A; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Ezugbaia, M; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kvaratskhelia, V; Metreveli, D; Morgan, J; Nasrullah, M; Shadaker, S; Sharvadze, L; Tsertsvadze, T, 2020) |
| "We selected patients with a liver fibrosis score of two or more who had not previously received antiviral treatment." | ( Yalaki, S; Yalcin, MS, 2020) |
| "In this study, a "TIIA-targets-liver fibrosis" network was constructed by combining the TIIA-specific and hepatic fibrosis-specific targets with protein-protein interactions (PPIS), and network pharmacology was applied to identify the potential targets and mechanisms of TIIA in the treatment of hepatic fibrosis." | ( Dong, BS; Shi, MJ; Su, SB; Yan, XL; Yang, WN; Zhang, H, 2020) |
| "Six patients (2%) had developed liver fibrosis while on MTX therapy." | ( Akasbi, N; Boudouaya, H; Harzy, T; Hilal, G; Salma, K, 2020) |
| "The carbon tetrachloride (CCl4)-induced liver fibrosis rat were treated with three doses of XYS." | ( Cai, FF; Chen, QL; Lu, YY; Su, SB; Wu, R; Zhang, H; Zhou, WJ; Zhou, Y, 2021) |
| "CHB patients with histologically proven liver cirrhosis who received TDF as the first-line therapy from 2012 to 2015 were recruited." | ( Ahn, SH; Chon, YE; Ha, Y; Han, KH; Hwang, SG; Jung, KS; Kim, DY; Kim, MN; Lee, JH; Park, JY, 2020) |
| "Therefore, patients with liver cirrhosis should be treated as if they are in a state of relative carnitine deficiency at the liver, skeletal muscle, and mitochondrial levels, even if the blood carnitine level is not decreased." | ( Hanai, T; Imai, K; Shimizu, M; Shiraki, M; Suetugu, A; Takai, K, 2020) |
| "The current research on the treatment of liver fibrosis mainly focuses on the activation of hepatic stellate cell, in addition to protecting liver cells." | ( Bai, J; Bi, Z; Li, H; Li, X; Ma, B; Ma, X; Ning, W; Shao, S; Wei, Y; Xie, C; Yang, C; Zhang, L; Zhang, R; Zhang, S; Zhou, H, 2020) |
| "In a model of liver fibrosis induced by administration of thioacetamide (TAA), inhibition of P2x7R with its selective inhibitor A438079 reversed TAA-induced liver damage and fibrosis." | ( Cui, BW; Jiang, M; Jin, Q; Lian, LH; Liu, J; Nan, JX; Qiao, CY; Shang, Y; Wu, YL; Yang, HX; Ye, H; Zhan, ZY; Zhang, Y, 2020) |
| "Liver fibrosis can develop into liver cirrhosis and hepatocellular carcinoma substantially without effective available treatment currently due to rarely characterized molecular pathogenesis." | ( Chen, Y; Deng, G; Gao, L; Huang, S; Lai, Y; Lv, Z; Mo, C; Xie, S; Yan, W; Zeng, T; Zhong, W; Zhou, C, 2020) |
| "Finally, the parameters of liver fibrosis were also reduced by the combination therapy more effectively than the monotherapy." | ( An, Y; Jia, L; Li, X; Liu, Q; Luo, G; Ouyang, J; Song, R; Zhang, B; Zhang, R, 2020) |
| "The discovery of drugs to treat liver fibrosis has long been a challenge over the past decades due to its complicated pathogenesis." | ( Guo, Y; Jiang, Y; Ma, X; Wen, J; Zeng, J; Zhao, Y, 2020) |
| "For this purpose, the rat model of liver fibrosis was treated with single or different compatibilities of herbals extracts for 4 weeks." | ( Cao, T; Cheng, J; Cui, Y; Fang, N; Kazemi, E; Lari Najafi, M; Lu, Y; Xue, B; Ye, B; Zhu, M, 2020) |
| "In the latter 3 groups, liver fibrosis was established by treatment with CCl4." | ( Li, MM; Li, XA; Nie, D; Zhou, Y; Zuo, L, 2021) |
| "Mice model of liver fibrosis was induced by thioacetamide (TAA), and liver tissues were collected at different time-points post-TAA administration." | ( Chen, L; Guo, J; Lin, J; Liu, W; Zeng, Z; Zhang, X, 2021) |
| "Hepatitis C virus (HCV) related liver cirrhosis is considered a major health problem; sofosbuvir (SOF)/ledipasvir (LDV) and SOF/daclatsvir (DACLA) are very promising direct antiviral agents (DAAS) especially in treating HCV genotype 4 which is the main genotype in Egypt." | ( Abbas, A; Elsayed, A; Hassan, H; Hassnine, A; M Abdelraheem, E, 2020) |
| "Exclusion criteria included liver cirrhosis and previous antiviral treatment." | ( Bair, MJ; Chang, CY; Chang, IW; Chen, CC; Chen, CY; Chen, JJ; Hsu, YC; Huang, YT; Ku, WH; Lee, TY; Lin, JT; Mo, LR; Tai, CM; Tseng, CH; Wu, CY; Wu, MS, 2021) |
| "To assess the risk of liver fibrosis in patients with rheumatoid arthritis treated with methotrexate, non-invasive, ultrasound-based elastography [acoustic radiation force impulse (ARFI) imaging] was applied." | ( Feuchtenberger, M; Kraus, L; Nigg, A; Schäfer, A; Schulze-Koops, H, 2021) |
| "No increased rate of liver fibrosis was found among RA patients treated with MTX." | ( Feuchtenberger, M; Kraus, L; Nigg, A; Schäfer, A; Schulze-Koops, H, 2021) |
| "In vivo liver fibrosis was induced in F344 rats using carbon tetrachloride by intraperitoneal injection for 8 weeks, and oral administration of lenvatinib was started two weeks after initial injection of carbon tetrachloride." | ( Akahane, T; Ishida, K; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Nishimura, N; Ogawa, H; Takagi, H; Takaya, H; Yoshiji, H, 2021) |
| "Cholestatic liver fibrosis occurs in liver injuries accompanied by inflammation, which develops into cirrhosis if not effectively treated in early stage." | ( Dai, M; Li, S; Liu, A; Lu, Z; Luo, J; Luo, Y; Qiu, J; Yang, J; Zheng, X, 2021) |
| "japonicum) egg-induced liver fibrosis, and gradually inhibited by genistein administration in infected mice." | ( Ding, C; Du, D; Huang, W; Li, D; Wang, D; Yu, S; Yuan, Q; Zhou, C, 2021) |
| "Unfortunately, a standard treatment for liver fibrosis has not been approved yet due to its complicated pathogenesis." | ( Elmorsy, MA; Ghanim, AMH; Metwaly, HA; Younis, NS, 2021) |
| "Another liver fibrosis model was established in CCl4 treated Sox9CreERT2ROSA26: YFP mice." | ( Kurata, W; Niitsu, Y; Nishimura, M; Sato, Y; Shimizu, F; Shimoyama, R; Tashiro, Y; Yoneda, A, 2021) |
| "In addition, BDL-induced liver fibrosis and inflammatory cell infiltration were reduced by PAL treatment at both day 5 and day 28 post-BDL." | ( Fan, Y; Jia, R; Li, L; Ma, L; Xie, J; Yang, F, 2021) |
| "Although the pathogenesis of liver fibrosis has been intensively studied, the choice of effective treatment is still inadequate." | ( Chang, KC; Cheng, PC; Lam, HYP; Lan, YC; Liang, TR; Peng, SY, 2022) |
| "PCZ administration in rats induced liver fibrosis through pathological changes, epithelial-mesenchymal transition, and collagen deposition." | ( Chang, YH; Han, SG; Jeong, CH; Kim, DH; Kim, DW; Kim, SH; Kim, YJ; Kwon, HC; Shin, DM; Sohn, H; Yune, JH, 2021) |
| "Fasudil inhibits liver fibrosis by activating NK cells and blocking hepatic stellate cell activation, thereby providing a feasible solution for the clinical treatment of liver fibrosis." | ( Guo, QJ; Han, QJ; Mu, YL; Su, YH; Zhang, J; Zhao, HJ; Zhao, RR, 2021) |
| "However, successful therapy for liver fibrosis is still lacking." | ( Ding, Y; Huang, C; Li, J; Ma, T; Xu, S; Zhang, Y; Zhao, H; Zhu, H, 2021) |
| "To determine if liver cirrhosis is associated with reduced efficacy of insulin-glucose treatment in moderate to severe hyperkalaemia." | ( Abasszade, JH; Crnobrnja, L; Jiang, C; Lim, AKH; Metlapalli, M; Pham, JH; Wang, RSH, 2021) |
| "A total of 272 patients with HBV-related liver fibrosis will be randomised into the combination therapy group or the monotherapy group at a 1:1 ratio." | ( Li, J; Li, X; Lin, L; Liu, Z; Mei, Y; Peng, L; Wu, L; Yuan, J; Zhu, S, 2021) |
| "Antifibrotic agent for the treatment of liver fibrosis has not been developed so far." | ( Hur, W; Jang, JW; Kang, BY; Kim, SJ; Kim, SM; Kwon, JH; Lee, HL; Lee, SW; Nam, H; Sung, PS; Yoo, SH; Yoon, SK, 2021) |
| "In the liver fibrosis mouse model, the fibrotic area and activated HSC markers were decreased by TDF but not ETV treatment." | ( Hur, W; Jang, JW; Kang, BY; Kim, SJ; Kim, SM; Kwon, JH; Lee, HL; Lee, SW; Nam, H; Sung, PS; Yoo, SH; Yoon, SK, 2021) |
| "Sprague-Dawley rats were induced with liver fibrosis by injections of diethylnitrosamine (DEN) and treated with or without MaR1 for four weeks." | ( González, DR; Herrera Vielma, F; Rodríguez, MJ; Sabaj, M; Tolosa, G; Zúñiga, MJ; Zúñiga-Hernández, J, 2021) |
| "To reduce the incidence of liver cirrhosis and HCC, NASH is targeted for the development of treatments, along with viral hepatitis and alcoholic hepatitis." | ( Aoyama, Y; Inaguma, S; Kato, H; Komura, M; Matsuo, Y; Nagayasu, Y; Naiki-Ito, A; Takahashi, S; Takiguchi, S; Tomita, M; Tsuda, H; Xiaochen, K, 2021) |
| "Its expression in experimental models of liver fibrosis correlates well with disease severity and treatment responses." | ( Adhyatmika, A; Beljaars, L; Gore, E; Mangnus, KA; Melgert, BN; Olinga, P; Putri, KSS; Reker-Smit, C; Schuppan, D, 2022) |
| "Malignancy; liver cirrhosis; dialysis treatment; increased Charlson comorbidity index, urea, and C-reactive protein values and the use of antineoplastic drugs are associated with mortality." | ( Bozkurt Babuş, S; Erdoğan, S; İyikesici, F; Kiraz, M; Köse, A, 2023) |
| "The pathogenesis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) remains unclear and the effective treatments have not been explored yet." | ( Cao, Y; Deng, S; Han, M; Hao, Y; Li, L; Li, R; Liang, P; Mai, W; Qin, Q; Xie, W; Yan, J; Yan, Y; Zhang, Y; Zhou, X; Zhou, Y; Zhu, L, 2022) |
| "Significant liver fibrosis regression occurs after hepatitis C virus (HCV) therapy." | ( Avihingsanon, A; Chuaypen, N; Hiranrat, P; Siripongsakun, S; Tangkijvanich, P; Tanpowpong, N, 2022) |
| "Antiviral therapy can alleviate liver fibrosis in chronic hepatitis B, but it has a limited effect on advanced liver fibrosis/cirrhosis." | ( Huang, JQ; Jiang, XG; Li, XD; Liang, J; Liu, CH; Liu, P; Lv, YH; Sun, KW; Xie, Q; Xing, HC; Zhang, B; Zhang, KJ; Zhang, W; Zhang, Y; Zhang, YX; Zhao, ZM; Zhu, CW; Zong, YL, 2022) |
| "There are few treatment options for liver cirrhosis and HCC, so it is vital to arrest these pathologies early in their development." | ( Beyoğlu, D; Idle, JR, 2022) |
| "To establish a treatment option for liver fibrosis, the possibility of the drug repurposing theory was investigated, with a focus on the off-target effects of active pharmaceutical ingredients." | ( Enomoto, H; Inamine, T; Kamimura, H; Kamimura, K; Ko, M; Kousaka, K; Miyamoto, H; Nagoya, T; Nakashima, M; Ohyama, K; Sakai, N; Sakamaki, A; Setsu, T; Soki, H; Tachiki, H; Terai, S; Tokunaga, A; Yokoo, T, 2023) |
| "When treated with XCHT, liver fibrosis was alleviated in both mice models, showing as the improvement of liver function, the protection of hepatocytes, the inhibition of HSC activation and the reduction of hepatic collagen accumulation." | ( Cao, W; Feng, YD; Li, WY; Li, XQ; Liu, CX; Liu, SY; Meng, JR; Sun, Y; Tian, W; Wang, SJ; Ye, W; Zhang, M, 2023) |
| "When treated with XCHT, liver fibrosis was alleviated in both mice models, showing as the improvement of liver function, the protection of hepatocytes, the inhibition of HSC activation and the reduction of hepatic collagen accumulation." | ( Cao, W; Feng, YD; Li, WY; Li, XQ; Liu, CX; Liu, SY; Meng, JR; Sun, Y; Tian, W; Wang, SJ; Ye, W; Zhang, M, 2023) |
| "However, effective therapy for liver fibrosis is still lacking." | ( Cai, J; Li, Q; Liu, X; Liu, Z; Ren, H; Wang, L; Xia, S; Yue, J; Zhang, H; Zhou, Q; Zhou, T; Zhou, X, 2023) |
| "In conclusion, sulodexide attenuated liver fibrosis in mice by restoration of differentiated LSECs, indicating that sulodexide treatment may present as a potential therapy for patients with liver fibrosis." | ( Chen, F; Cui, YL; Deng, J; Huang, R; Liu, SQ; Tao, X; Xie, WF; Zhang, X; Zhu, CP, 2023) |
| "Preoperative assessment of the degree of liver fibrosis is important to determine treatment strategies." | ( Daisaki, H; Hayashi, N; Iwasa, H; Kume, T; Tokorodani, R; Yamagami, T, 2023) |
| "Nucleotide analogs treatment can reverse liver fibrosis in chronic hepatitis B (CHB)." | ( Chen, M; Deng, X; Feng, L; Han, Z; Huang, J; Jiang, K; Peng, D; Tong, G; Wang, Y; Xing, Y; Xu, L; Zeng, H; Zhong, W; Zhou, D; Zhou, H, 2023) |
| "This work provides a novel strategy for liver fibrosis treatment based on sinusoidal perfusion enhancement and apoptosis inhibition." | ( Cheng, X; Cheng, Z; Li, C; Li, F; Nie, G; Qi, F; Sun, J; Wu, Z; Zhao, Y, 2023) |
| "The dynamics of liver fibrosis in CCl4-treated animals were greater than in the D-GalN groups." | ( Bogunia, E; Czekaj, P; Grajoszek, A; Hermyt, M; Kolanko, E; Król, M; Limanówka, Ł; Michalik, M; Pająk, J; Prusek, A; Sikora, B; Skubis-Sikora, A, 2023) |
| "The dynamics of liver fibrosis in CCl4 treated rodents is greater than in the D-GalN treated ones." | ( Bogunia, E; Czekaj, P; Grajoszek, A; Hermyt, M; Kolanko, E; Król, M; Limanówka, Ł; Michalik, M; Pająk, J; Prusek, A; Sikora, B; Skubis-Sikora, A, 2023) |
| "Before and after treatment, serum liver fibrosis 4 items [type IV collagen (IV-C), hyaluronidase (HA), type III procollagen (PC III), laminin (LN)], liver function and cholestasis-related markers [total bilirubin (TBil), direct bilirubin (DBil), total bile acid (TBA), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST)], oxidative stress markers [superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH)], liver stiffness measurement (LSM) detected by transient elastography (TE), aspartate aminotransferase-to-platelet ratio index (APRI), and liver and spleen retraction time were recorded in the two groups." | ( Li, H; Ma, X; Su, M; Tang, J; Yan, S; Yi, W, 2023) |
| "After treatment, the liver fibrosis 4 items, liver function and cholestasis-related markers, LSM, and APRI were all significantly decreased in both groups, and the indexes in the Li-Dan-He-Ji group were significantly lower than those in the conventional treatment group [HA (ng/L): 165." | ( Li, H; Ma, X; Su, M; Tang, J; Yan, S; Yi, W, 2023) |
| "To date, liver fibrosis has no clinically approved treatment." | ( Afify, EA; Darwish, IE; El-Ganainy, SO; El-Mezayen, NS; Noah, AA, 2023) |
| "To study the prevalence of liver fibrosis (LF) measured by FibroScan and APRI index in patients with rheumatoid arthritis (AR) undergoing treatment with methotrexate (MTX)." | ( Belzunegui Otaño, JM; Castiella Eguzkiza, A; de Diego-Sola, A; López Domínguez, LM; Sánchez Iturri, MJ; Urreta Barallobre, I; Zapata Morcillo, EM, 2023) |
| "End-stage of liver fibrosis as a precancerous state could lead to cirrhosis and hepatocellular carcinoma which liver transplantation is the only effective treatment." | ( Alizadeh, E; Azizsoltani, A; Baghaei, K; Hatami, B; Mahdavi, V; Zali, MR, 2023) |
| "B cells can promote liver fibrosis, but the mechanism of B cell infiltration and therapy against culprit B cells are lacking." | ( Dai, W; Gao, J; Huang, Z; Tang, C; Tong, H; Yang, W; Zhang, L; Zhao, C, 2023) |
| "Brg1 promotes the progression of liver fibrosis in mice and may therefore be used as a potential therapeutic target for treating patients with liver fibrosis due to chronic injury." | ( Cheng, Z; Friess, H; Hartmann, D; Hüser, N; Kaufmann, B; Mogler, C; Schmid, RM; von Figura, G; Wang, B; Yin, Y; Zhong, S, 2023) |